$avrw 2021 Q2 10-Q

Concept	2021 Q2	2020 Q2
Revenue	$2.109M	$269.0K
YoY Change	684.01%	5280.0%
Cost Of Revenue	$797.0K	$100.0K
YoY Change	697.0%	3233.33%
Gross Profit	$1.312M	$169.0K
YoY Change	676.33%	8350.0%
Gross Profit Margin	62.21%	62.83%
Selling, General & Admin	$4.772M	$2.511M
YoY Change	90.04%	-53.29%
% of Gross Profit	363.72%	1485.8%
Research & Development	$699.0K	$735.0K
YoY Change	-4.9%	-32.82%
% of Gross Profit	53.28%	434.91%
Depreciation & Amortization	$40.00K	$50.00K
YoY Change	-20.0%	-77.94%
% of Gross Profit	3.05%	29.59%
Operating Expenses	$4.577M	$13.64M
YoY Change	-66.43%	-9.03%
Operating Profit	-$3.265M	-$13.47M
YoY Change	-75.76%	-10.15%
Interest Expense	-$133.0K	$2.000K
YoY Change	-6750.0%	-100.05%
% of Operating Profit
Other Income/Expense, Net	$1.944M	$28.00K
YoY Change	6842.86%	-104.87%
Pretax Income	-$1.321M	-$13.44M
YoY Change	-90.17%	-40.76%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.321M	-$13.44M
YoY Change	-90.17%	-40.73%
Net Earnings / Revenue	-62.64%	-4995.91%
Basic Earnings Per Share	-$0.02	-$0.32
Diluted Earnings Per Share	-$0.02	-$0.32
COMMON SHARES
Basic Shares Outstanding	59.84M shares	41.72M shares
Diluted Shares Outstanding	59.84M shares	41.72M shares

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.701M	$1.429M
YoY Change	19.03%	-81.31%
Cash & Equivalents	$1.701M	$1.429M
Short-Term Investments
Other Short-Term Assets	$123.0K	$655.0K
YoY Change	-81.22%	-33.74%
Inventory	$831.0K	$228.0K
Prepaid Expenses	$102.0K
Receivables	$242.0K	$46.00K
Other Receivables	$0.00	$2.000K
Total Short-Term Assets	$3.290M	$2.339M
YoY Change	40.66%	-73.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.947M	$2.052M
YoY Change	-5.12%	83.81%
Goodwill	$13.87M
YoY Change
Intangibles	$11.87M
YoY Change
Long-Term Investments	$509.0K	$509.0K
YoY Change	0.0%
Other Assets	$83.00K	$35.00K
YoY Change	137.14%	-56.21%
Total Long-Term Assets	$41.14M	$27.73M
YoY Change	48.38%	4.59%
TOTAL ASSETS
Total Short-Term Assets	$3.290M	$2.339M
Total Long-Term Assets	$41.14M	$27.73M
Total Assets	$44.43M	$30.07M
YoY Change	47.78%	-14.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.015M	$1.373M
YoY Change	46.76%	154.5%
Accrued Expenses	$3.808M	$336.0K
YoY Change	1033.33%	88.41%
Deferred Revenue
YoY Change
Short-Term Debt	$2.146M	$1.265M
YoY Change	69.64%	101.78%
Long-Term Debt Due	$8.473M	$11.00K
YoY Change	76927.27%
Total Short-Term Liabilities	$17.04M	$3.305M
YoY Change	415.55%	64.64%
LONG-TERM LIABILITIES
Long-Term Debt	$4.323M	$46.00K
YoY Change	9297.83%
Other Long-Term Liabilities	$1.877M	$85.00K
YoY Change	2108.24%	-99.63%
Total Long-Term Liabilities	$6.200M	$131.0K
YoY Change	4632.82%	-99.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.04M	$3.305M
Total Long-Term Liabilities	$6.200M	$131.0K
Total Liabilities	$23.24M	$3.436M
YoY Change	576.34%	-86.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$85.75M
YoY Change
Common Stock	$63.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.19M	$26.72M
YoY Change
Total Liabilities & Shareholders Equity	$44.43M	$30.16M
YoY Change	47.34%	-14.68%

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$1.321M	-$13.44M
YoY Change	-90.17%	-40.73%
Depreciation, Depletion And Amortization	$40.00K	$50.00K
YoY Change	-20.0%	-77.94%
Cash From Operating Activities	$1.119M	-$1.793M
YoY Change	-162.41%	-49.17%
INVESTING ACTIVITIES
Capital Expenditures	-$38.00K	-$361.0K
YoY Change	-89.47%	-53.41%
Acquisitions
YoY Change
Other Investing Activities	-$200.0K	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$238.0K	-$361.0K
YoY Change	-34.07%	-104.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	340.0K	2.001M
YoY Change	-83.01%	131.18%
NET CHANGE
Cash From Operating Activities	1.119M	-1.793M
Cash From Investing Activities	-238.0K	-361.0K
Cash From Financing Activities	340.0K	2.001M
Net Change In Cash	1.221M	-153.0K
YoY Change	-898.04%	-103.03%
FREE CASH FLOW
Cash From Operating Activities	$1.119M	-$1.793M
Capital Expenditures	-$38.00K	-$361.0K
Free Cash Flow	$1.157M	-$1.432M
YoY Change	-180.8%	-47.98%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	62877959	shares
CY2021Q2	us-gaap	Cash Cash	1701000	USD
CY2020Q4	us-gaap	Cash Cash	1725000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	242000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	224000	USD
CY2021Q2	us-gaap	Notes Receivable Net NotesReceivableNet	0	USD
CY2020Q4	us-gaap	Notes Receivable Net NotesReceivableNet	0	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	831000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	449000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	516000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1452000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	3290000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	3850000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1947000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2074000	USD
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	46000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	242000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	831000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	52000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	301000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	343000	USD
CY2021Q2	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	200000	USD
CY2020Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	0	USD
CY2021Q2	us-gaap	Investments Investments	509000	USD
CY2020Q4	us-gaap	Investments Investments	509000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	13868000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	13868000	USD
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11869000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1711000	USD
CY2021Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3867000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	14288000	USD
CY2021Q2	curr	Customer Relationships Tradename And Non Compete Net CustomerRelationshipsTradenameAndNonCompeteNet	8452000	USD
CY2020Q4	curr	Customer Relationships Tradename And Non Compete Net CustomerRelationshipsTradenameAndNonCompeteNet	9606000	USD
CY2021Q2	us-gaap	Other Assets OtherAssets	83000	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	58000	USD
CY2021Q2	us-gaap	Assets Assets	44432000	USD
CY2020Q4	us-gaap	Assets Assets	46359000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2015000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2135000	USD
CY2021Q2	curr	Accrued Expenses Net AccruedExpensesNet	3708000	USD
CY2020Q4	curr	Accrued Expenses Net AccruedExpensesNet	1299000	USD
CY2021Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	12000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	12000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	93000	USD
CY2021Q2	us-gaap	Loans Payable LoansPayable	46000	USD
CY2020Q4	us-gaap	Loans Payable LoansPayable	265000	USD
CY2021Q2	us-gaap	Program Rights Obligations ProgramRightsObligations	0	USD
CY2020Q4	us-gaap	Program Rights Obligations ProgramRightsObligations	605000	USD
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1240000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1040000	USD
CY2021Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1550000	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	800000	USD
CY2021Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	550000	USD
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	550000	USD
CY2021Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	7221000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	6674000	USD
CY2021Q2	us-gaap	Deposit Contracts Liabilities DepositContractsLiabilities	597000	USD
CY2020Q4	us-gaap	Deposit Contracts Liabilities DepositContractsLiabilities	994000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	17039000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14467000	USD
CY2021Q2	curr	License Fees LicenseFees	0	USD
CY2020Q4	curr	License Fees LicenseFees	80000	USD
CY2021Q2	curr	Finance Lease Payable FinanceLeasePayable	34000	USD
CY2020Q4	curr	Finance Lease Payable FinanceLeasePayable	40000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	227000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	278000	USD
CY2021Q2	curr	Fair Value Convertible Promissory Notes Nets FairValueConvertiblePromissoryNotesNets	4289000	USD
CY2020Q4	curr	Fair Value Convertible Promissory Notes Nets FairValueConvertiblePromissoryNotesNets	7010000	USD
CY2021Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	1650000	USD
CY2020Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	3205000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	23239000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	25080000	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62877959	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59476268	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	63000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	60000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	106272000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101807000	USD
CY2021Q2	us-gaap	Common Unit Issuance Value CommonUnitIssuanceValue	603000	USD
CY2020Q4	us-gaap	Common Unit Issuance Value CommonUnitIssuanceValue	665000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85745000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81253000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	21193000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	21279000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44432000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46359000	USD
CY2021Q2	curr	Product Sales Net Of Discounts And Refunds ProductSalesNetOfDiscountsAndRefunds	2066000	USD
CY2020Q2	curr	Product Sales Net Of Discounts And Refunds ProductSalesNetOfDiscountsAndRefunds	163000	USD
	curr	Product Sales Net Of Discounts And Refunds ProductSalesNetOfDiscountsAndRefunds	3447000	USD
	curr	Product Sales Net Of Discounts And Refunds ProductSalesNetOfDiscountsAndRefunds	366000	USD
CY2021Q2	us-gaap	Other Income OtherIncome	25000	USD
CY2020Q2	us-gaap	Other Income OtherIncome	100000	USD
	us-gaap	Other Income OtherIncome	52000	USD
	us-gaap	Other Income OtherIncome	169000	USD
CY2021Q2	curr	Shipping And Other Sales ShippingAndOtherSales	18000	USD
CY2020Q2	curr	Shipping And Other Sales ShippingAndOtherSales	6000	USD
	curr	Shipping And Other Sales ShippingAndOtherSales	56000	USD
	curr	Shipping And Other Sales ShippingAndOtherSales	14000	USD
CY2021Q2	us-gaap	Revenues Revenues	2109000	USD
CY2020Q2	us-gaap	Revenues Revenues	269000	USD
	us-gaap	Revenues Revenues	3555000	USD
	us-gaap	Revenues Revenues	549000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	797000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1214000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	201000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	1312000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	169000	USD
	us-gaap	Gross Profit GrossProfit	2341000	USD
	us-gaap	Gross Profit GrossProfit	348000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	699000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	735000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1343000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1540000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4772000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2511000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10316000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4635000	USD
CY2021Q2	curr	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	-894000	USD
CY2020Q2	curr	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	10390000	USD
	curr	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	-1555000	USD
	curr	Change In Fair Value Of Contingent Stock Consideration ChangeInFairValueOfContingentStockConsideration	5658000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	4577000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	13636000	USD
	us-gaap	Operating Expenses OperatingExpenses	10104000	USD
	us-gaap	Operating Expenses OperatingExpenses	11833000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3265000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13467000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7763000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11485000	USD
CY2021Q2	us-gaap	Interest Income Operating InterestIncomeOperating	1000	USD
CY2020Q2	us-gaap	Interest Income Operating InterestIncomeOperating	5000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	2000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	20000	USD
CY2021Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	2434000	USD
CY2020Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	26000	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	2434000	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	26000	USD
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	335000	USD
CY2020Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	734000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2020Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-41000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2021Q2	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	0	USD
CY2020Q2	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	12000	USD
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	0	USD
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	75000	USD
CY2021Q2	curr	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-692000	USD
CY2020Q2	curr	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	0	USD
	curr	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	340000	USD
	curr	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	0	USD
CY2021Q2	us-gaap	Interest Expense Other InterestExpenseOther	134000	USD
CY2020Q2	us-gaap	Interest Expense Other InterestExpenseOther	15000	USD
	us-gaap	Interest Expense Other InterestExpenseOther	199000	USD
	us-gaap	Interest Expense Other InterestExpenseOther	28000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1944000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3270000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	93000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1321000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13439000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4493000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11392000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1321000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-13439000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4493000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11392000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59842904	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41716558	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48299751	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39867063	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59842904	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41716558	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48299751	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39867063	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	21279000	USD
CY2021Q1	curr	Issuance Of Common Stock For Professional Services Amount IssuanceOfCommonStockForProfessionalServicesAmount	508000	USD
CY2021Q1	curr	Issuance Of Common Stock From The Equity Incentive Plan Amount IssuanceOfCommonStockFromTheEquityIncentivePlanAmount	138000	USD
CY2021Q1	curr	Issuance Of Common Stock For Exercise Of Warrants Amount IssuanceOfCommonStockForExerciseOfWarrantsAmount	0	USD
CY2021Q1	curr	Fair Value Of Stock Options And Restricted Stock Granted FairValueOfStockOptionsAndRestrictedStockGranted	961000	USD
CY2021Q1	curr	Fair Value Of Restricted Stock Units Granted FairValueOfRestrictedStockUnitsGranted	144000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3171000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	19859000	USD
CY2021Q2	curr	Issuance Of Common Stock For Professional Services Amount IssuanceOfCommonStockForProfessionalServicesAmount	243000	USD
CY2021Q2	curr	Issuance Of Common Stock From The Equity Incentive Plan Amount IssuanceOfCommonStockFromTheEquityIncentivePlanAmount	-157000	USD
CY2021Q2	curr	Issuance Of Common Stock From Conversion Of Convertible Promissory Notes Amount IssuanceOfCommonStockFromConversionOfConvertiblePromissoryNotesAmount	1835000	USD
CY2021Q2	curr	Fair Value Of Stock Options And Restricted Stock Granted FairValueOfStockOptionsAndRestrictedStockGranted	591000	USD
CY2021Q2	curr	Fair Value Of Restricted Stock Units Granted FairValueOfRestrictedStockUnitsGranted	143000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1321000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	21193000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	13507000	USD
CY2020Q1	curr	Issuance Of Common Stock For Professional Services Amount IssuanceOfCommonStockForProfessionalServicesAmount	231000	USD
CY2020Q1	curr	Fair Value Of Stock Options And Restricted Stock Granted FairValueOfStockOptionsAndRestrictedStockGranted	469000	USD
CY2020Q1	curr	Fair Value Of Restricted Stock Units Granted FairValueOfRestrictedStockUnitsGranted	60000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	2046000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	16313000	USD
CY2020Q2	curr	Issuance Of Common Stock For Professional Services Amount IssuanceOfCommonStockForProfessionalServicesAmount	189000	USD
CY2020Q2	curr	Issuance Of Common Stock From The Equity Incentive Plan Amount IssuanceOfCommonStockFromTheEquityIncentivePlanAmount	0	USD
CY2020Q2	curr	Issuance Of Common Stock From Exercise Of Warrants Amount IssuanceOfCommonStockFromExerciseOfWarrantsAmount	1418000	USD
CY2020Q2	curr	Issuance Of Common Stock From Settlement With Chemistry Holdings Inc Amount IssuanceOfCommonStockFromSettlementWithChemistryHoldingsIncAmount	21701000	USD
CY2020Q2	curr	Fair Value Of Stock Options And Restricted Stock Granted FairValueOfStockOptionsAndRestrictedStockGranted	479000	USD
CY2020Q2	curr	Fair Value Of Restricted Stock Units Granted FairValueOfRestrictedStockUnitsGranted	60000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-13439000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	26721000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4493000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11392000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	752000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	420000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	0	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	300000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	19000	USD
	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	USD
	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable	0	USD
	curr	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable	26000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	734000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-1555000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	5658000	USD
	curr	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	340000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1578000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	164000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	48000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	6000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	586000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	25000	USD
	curr	Common Stock Issued For Settlement Of Earnout Liabilities From The Acquisition Of Chemistry Holdings Inc CommonStockIssuedForSettlementOfEarnoutLiabilitiesFromTheAcquisitionOfChemistryHoldingsInc	0	USD
	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	200000	USD
	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable	200000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-99000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-844000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1417000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	750000	USD
CY2021Q2	curr	Accumulated Deficits AccumulatedDeficits	-13700000	USD
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	80000.00	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	40000.00	USD
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	41000	USD
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	14000	USD
	curr	Recovery Of Bad Debt Expense RecoveryOfBadDebtExpense	221000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	41000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	curr	Inventory Reserve For Obsolescence InventoryReserveForObsolescence	109000	USD
	curr	Inventory Reserve For Obsolescence InventoryReserveForObsolescence	2000	USD
	curr	Common Stock Issued For Conversion Of Promissory Notes And Accrued Interest CommonStockIssuedForConversionOfPromissoryNotesAndAccruedInterest	0	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	75000	USD
	curr	Fair Value Of Vested Stock Options And Restricted Stock FairValueOfVestedStockOptionsAndRestrictedStock	1839000	USD
	curr	Fair Value Of Vested Stock Options And Restricted Stock FairValueOfVestedStockOptionsAndRestrictedStock	1069000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-59000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	85000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	273000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	52000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	957000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-36000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-95000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	139000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2538000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	113000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-6000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-6000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	44000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-397000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-152000	USD
	us-gaap	Taxes And Licenses TaxesAndLicenses	80000	USD
	us-gaap	Taxes And Licenses TaxesAndLicenses	5000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-656000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3778000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	0	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	250000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	67000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	649000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	200000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	219000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	111000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	731000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1955000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-24000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2667000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1725000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4096000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1701000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1429000	USD
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	1000000.0	USD
CY2021Q2	curr	Customer Deposits For Commercial Products CustomerDepositsForCommercialProducts	597000	USD
CY2020Q4	curr	Customer Deposits For Commercial Products CustomerDepositsForCommercialProducts	281000	USD
CY2021Q2	curr	Customer Deposits For Personal Protective Equipment CustomerDepositsForPersonalProtectiveEquipment	0	USD
CY2020Q4	curr	Customer Deposits For Personal Protective Equipment CustomerDepositsForPersonalProtectiveEquipment	713000	USD
CY2021Q2	us-gaap	Deposit Contracts Liabilities DepositContractsLiabilities	597000	USD
CY2020Q4	us-gaap	Deposit Contracts Liabilities DepositContractsLiabilities	994000	USD
CY2020	curr	Contract Liabilities Beginning Balance ContractLiabilitiesBeginningBalance	456000	USD
CY2020	curr	Additions To Contract Liabilities AdditionsToContractLiabilities	1033000	USD
CY2020	curr	Transfers To Revenue TransfersToRevenue	-495000	USD
	curr	Additions To Contract Liabilities AdditionsToContractLiabilities	591000	USD
	curr	Customer Deposits Returned CustomerDepositsReturned	-713000	USD
	curr	Transfers To Revenue TransfersToRevenue	-275000	USD
	curr	Contract Liabilities Ending Balance ContractLiabilitiesEndingBalance	597000	USD
	us-gaap	Advertising Expense AdvertisingExpense	1000000.0	USD
CY2020Q2	curr	Research And Development Expenses ResearchAndDevelopmentExpenses	700000	USD
	curr	Research And Development Expenses ResearchAndDevelopmentExpenses	1500000	USD
CY2021Q2	curr	Valuation Allowance Percentage ValuationAllowancePercentage	1	pure
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3200000	USD
	curr	Notes Payable Fair Value NotesPayableFairValue	18684	USD
	curr	Changes In Fair Value Of Series A Note ChangesInFairValueOfSeriesANote	-886000	USD
	curr	Change In Fair Value Of Series B Notes ChangeInFairValueOfSeriesBNotes	546000	USD
	curr	Conversion Of Series A Notes ConversionOfSeriesANotes	-1834000	USD
	curr	Fair Value Of Series A And B Notes FairValueOfSeriesAAndBNotes	16510	USD
	curr	Conversion Price ConversionPrice	0.51
CY2020	curr	Stock Price StockPrice	1.30
	curr	Stock Price StockPrice	1.32
CY2020	curr	Conversion Price ConversionPrice	1.32
	curr	Interest Rate InterestRate	0.18	pure
CY2021Q2	us-gaap	Servicing Asset At Fair Value Other Changes In Fair Value ServicingAssetAtFairValueOtherChangesInFairValue	700000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1400000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-13439000	USD
	us-gaap	Interest Paid Net InterestPaidNet	68000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3000	USD
	curr	Common Stock Issued For Conversion Of Promissory Notes And Accrued Interest CommonStockIssuedForConversionOfPromissoryNotesAndAccruedInterest	1834000	USD
	curr	Common Stock Issued For Settlement Of Earnout Liabilities From The Acquisition Of Chemistry Holdings Inc CommonStockIssuedForSettlementOfEarnoutLiabilitiesFromTheAcquisitionOfChemistryHoldingsInc	21701000	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by GAAP for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2021, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2021 and 2020, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in Form 10-K for the fiscal period ended December 31, 2020 filed with the SEC on March 31, 2021.</p>
CY2021Q2	curr	Working Capital Deficit WorkingCapitalDeficit	-85800000	USD
CY2021Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	700000	USD
	us-gaap	Payments For Brokerage Fees PaymentsForBrokerageFees	700000	USD
CY2021Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	2300000	USD
	us-gaap	Reclassifications Reclassifications	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Certain reclassifications have been made to prior year’s consolidated financial statements to enhance comparability with the current year’s consolidated financial statements. These reclassifications had no effect on the previously reported net loss.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include, but are not limited to, the allowance for doubtful accounts, valuation of intangible assets and goodwill, depreciative and amortization useful lives, assumptions used to calculate the fair value of the contingent share consideration, stock based compensation, beneficial conversion features, warrant values, deferred taxes and the assumptions used to calculate derivative liabilities and fair values of the purchase price allocations and convertible promissory notes. Actual results could differ materially from such estimates under different assumptions or circumstances. </p>
CY2021Q2	curr	Outstanding Shares Of Common Stock OutstandingSharesOfCommonStock	20000000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	59842904000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41716558000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48299751000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39867063000	shares
CY2021Q2	curr	Common Stock And Common Stock Equivalents CommonStockAndCommonStockEquivalents	59842904000	shares
CY2020Q2	curr	Common Stock And Common Stock Equivalents CommonStockAndCommonStockEquivalents	41716558000	shares
	curr	Common Stock And Common Stock Equivalents CommonStockAndCommonStockEquivalents	48299751000	shares
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2021Q2	curr	Vested Stock Options From The Companys2017 Equity Incentive Plan VestedStockOptionsFromTheCompanys2017EquityIncentivePlan	3471304	shares
	curr	Vested Stock Options From The Companys2017 Equity Incentive Plan VestedStockOptionsFromTheCompanys2017EquityIncentivePlan	3460767	shares
CY2021Q2	curr	Warrants Shares WarrantsShares	2264091	shares
	curr	Warrants Shares WarrantsShares	6648446	shares
	curr	Shares To Be Issued Upon Conversion Of Convertible Payable SharesToBeIssuedUponConversionOfConvertiblePayable	115047	shares
CY2021Q2	curr	Shares To Be Issued Upon Conversion Of Convertible Payable SharesToBeIssuedUponConversionOfConvertiblePayable	115047	shares
CY2021Q2	curr	Total Anti Dilutive Shares TotalAntiDilutiveShares	5850442	shares
	curr	Total Anti Dilutive Shares TotalAntiDilutiveShares	10224260	shares
	curr	Cost To Obtain A Contractpolicytextblock CostToObtainAContractpolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company pays sales commission to its employees and outside sales representatives for contracts that they obtain relating to wholesale and personal protective equipment. The Company applies the optional practical expedient to immediately expense costs to obtain a contract if the amortization period of the asset that would have been recognized is one year or less. As such, sales commissions are immediately recognized as an expense and included as part of sales and marketing expenses.</p>
	curr	Contingent Consideration Liabilitiespolicytextblock ContingentConsiderationLiabilitiespolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Certain of the Company’s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined upon attainment of revenue milestones, from product sales, as applicable. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of revenues generated from the Sera Labs’ products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The fair value of contingent consideration after the acquisition date is reassessed by the Company as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that the Company records in its consolidated financial statements. See Note 19 for a full discussion of these liabilities.</p>
	curr	Cure Pharmaceutical Revenuepolicytexkblock CurePharmaceuticalRevenuepolicytexkblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Cure Pharmaceutical derives revenues from two primary sources: products and services. Product revenue includes the shipment of products according to agreements with the Cure Pharmaceutical’s customers. Services include research and development contracts for the development of OTF products utilizing the Cure Pharmaceutical’s CureFilm Technology or our other proprietary technologies. Cure Pharmaceutical’s contracts with customers rarely contain multiple performance obligations. For these contracts, Cure Pharmaceutical accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Standalone selling prices are typically estimated based on observable transactions when these services are sold on a standalone basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Cure Pharmaceutical’s formulation and product development income include services for the development of OTF products utilizing our CureFilm Technology. Our development contracts can have up to four phases. Revenue is recognized based on progress toward completion of the performance obligation in each phase. The method to measure progress toward completion requires judgment and is based on the nature of the products or services to be provided. Cure Pharmaceutical generally uses the input method to measure progress for its contracts because it best depicts the transfer of assets to the customer, which occurs as we incur costs for the contracts. Under the cost-to-cost measure of progress, the progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. Revenue is recorded proportionally as costs are incurred. Costs to fulfill these obligations mainly include materials, labor, supplies and consultants.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.4pt; text-align:justify;">Cure Pharmaceutical has entered into a Collaboration and Joint Development Agreement (“Agreement”) with Medolife Rx (“Medolife”) on February 1, 2021 (“Effective Date”) for Medolife to produce Medolife Products (“Products”) in Cure Pharmaceutical’s cGMP facility. The term of this agreement is for five (5) years from the Effective Date (“Term”). Medolife is to pay $0.3 million to assist in completing the jointly developed production line at Cure Pharmaceutical’s cGMP facility. In addition, Cure Pharmaceutical will produce Products on behalf of Medolife and will grant access to Medolife for a joint production area within Cure Pharmaceutical’s production facility for the Term of this Agreement. The Company has determined that there are no distinct obligations for the $0.3 million and Cure Pharmaceutical does have further obligations as stated in the Agreement, thus the Company will recognize the revenue monthly over the Term, beginning February 1, 2021. </p>
CY2020Q4	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	300000	USD
	curr	Sera Labs Revenuepolicytexkblock SeraLabsRevenuepolicytexkblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Sera Labs recognizes revenue as, or when, we satisfy performance obligations under a contract. We account for a contract when the parties approved the contract and are committed to perform on it, the rights of each party and the payment terms are identified, the contract has commercial substance and it is probable that we will collect substantially all of the consideration. A performance obligation is a promise in a contract to transfer a distinct good or service, or a series of distinct goods or services, to a customer. The transaction price of a contract must be allocated to each performance obligation and recognized as the performance obligation is satisfied. In essence, we recognize revenue when or as control of the promised goods or services transfer to the customer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt; text-align:justify;">Revenue from eCommerce sales, including direct-to-consumer sales, are recognized upon shipment of merchandise. We also elected to adopt the practical expedient related to shipping and handling fees which allows us to account for shipping and handling activities that occur after control of the related good transfers as fulfillment activities instead of assessing such activities as performance obligations. Therefore, shipping and handling activities are considered part of the Company’s obligation to transfer the products and therefore are recorded as direct selling expenses, as incurred. Shipping revenue are recorded upon delivery to the customer.</p>
	curr	Practical Expedients And Exemptionspolicytextblock PracticalExpedientsAndExemptionspolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company has elected certain practical expedients and policy elections as permitted under ASC Topic 606 as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company adopted the practical expedient related to not adjusting the promised amount of consideration for the effects of a significant financing component if the period between transfer of product and customer payment is expected to be less than one year at the time of contract inception;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company made the accounting policy election to exclude any sales and similar taxes from the transaction price;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company adopted the practical expedient not to disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less</p></td></tr></tbody></table>
	curr	Sales Taxpolicytextblock SalesTaxpolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to a customer, excluding sales taxes. The net amount of sales tax payable to the taxation authority is included sales tax payable in the balance sheet.</p>
	curr	Sales Returns Discounts And Warrantiespolicytextblock SalesReturnsDiscountsAndWarrantiespolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Sales returns, discount and warranties are considered variable consideration under ASC 606. The Company reduces revenue for estimated future returns, discounts and warranties which may occur with distributors and retailers. When evaluating the adequacy of sales returns, discounts and warranties, the Company analyzes the following: historical credit allowances, current sell-through of inventory of the Company’s products, current trends in retail industry, changes in customer demand, acceptance of products, and other related factors.</p>
CY2020Q4	curr	Prepaid Consulting Services PrepaidConsultingServices	14000	USD
CY2021Q2	curr	Prepaid Clinical Study PrepaidClinicalStudy	0	USD
CY2020Q4	curr	Prepaid Clinical Study PrepaidClinicalStudy	32000	USD
CY2021Q2	us-gaap	Prepaid Insurance PrepaidInsurance	138000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	347000	USD
CY2021Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	0	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	700000	USD
CY2021Q2	curr	Prepaid Equipment PrepaidEquipment	61000	USD
CY2020Q4	curr	Prepaid Equipment PrepaidEquipment	61000	USD
CY2021Q2	curr	Prepaid Inventory PrepaidInventory	175000	USD
CY2020Q4	curr	Prepaid Inventory PrepaidInventory	211000	USD
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	102000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	66000	USD
	curr	Contract Liabilitiespolicytextblcok ContractLiabilitiespolicytextblcok	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Advance payments and billings in excess of revenue recognized represent contract liabilities and are recorded as deferred revenues when customers remit contractual cash payments in advance before satisfying performance obligations under contractual arrangements. Contract liabilities are derecognized when revenue is recognized, and the performance obligation is satisfied. Advance payments and billings in excess of revenue recognized are included in deferred revenue, which is classified as current or noncurrent based on the timing of when the Company expects to recognize revenue. At June 30, 2021 and December 31, 2020, we had contract liabilities of $0.6 million and $1.0 million, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Contract liabilities is made up of the following as of June 30, 2021 and December 31, 2020 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Customer deposits for commercial products</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">597</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">281</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Customer deposits for personal protective equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">713</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total contract liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">597</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">994</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The following table summarizes the changes in contract liabilities during the six months ended June 30, 2021 and year ended December 31, 2020 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at December 31, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">456</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt">Additions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,033</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 13.7pt">Transfers to Revenue</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(495 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">994</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 13.7pt">Additions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">591</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 13.7pt">Customer deposits returned</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(713 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 13.7pt">Transfers to Revenue</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(275 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">597</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p>
CY2021Q2	us-gaap	Deferred Revenue DeferredRevenue	600000	USD
	curr	Contract Liabilities Beginning Balance ContractLiabilitiesBeginningBalance	994000	USD
	us-gaap	Advertising Expense AdvertisingExpense	1600000	USD
CY2021Q2	curr	Research And Development Expenses ResearchAndDevelopmentExpenses	700000	USD
	curr	Research And Development Expenses ResearchAndDevelopmentExpenses	1300000	USD
CY2021Q2	us-gaap	Other Assets Current OtherAssetsCurrent	123000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	79000	USD
CY2021Q2	curr	Prepaid Expenses And Other Assets PrepaidExpensesAndOtherAssets	599000	USD
CY2021Q2	curr	Current Portion Of Prepaid Expenses And Other Assets CurrentPortionOfPrepaidExpensesAndOtherAssets	-516000	USD
CY2020Q4	curr	Current Portion Of Prepaid Expenses And Other Assets CurrentPortionOfPrepaidExpensesAndOtherAssets	-1452000	USD
CY2021Q2	us-gaap	Other Assets OtherAssets	83000	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	58000	USD
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	67000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	64000	USD
CY2021Q2	curr	Inventory Packaging Components InventoryPackagingComponents	133000	USD
CY2020Q4	curr	Inventory Packaging Components InventoryPackagingComponents	54000	USD
CY2021Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	101000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	22000	USD
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	714000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	603000	USD
CY2021Q2	us-gaap	Inventory Gross InventoryGross	1015000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	743000	USD
CY2021Q2	us-gaap	Inventory Adjustments InventoryAdjustments	-184000	USD
CY2020Q4	us-gaap	Inventory Adjustments InventoryAdjustments	-294000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	831000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	449000	USD
	curr	Inventory Reserves InventoryReserves	3000.000	USD
CY2020Q2	curr	Inventory Reserves InventoryReserves	1000.000	USD
	curr	Inventory Reserves InventoryReserves	3000.000	USD
CY2020Q4	us-gaap	Sale Leaseback Transaction Accumulated Depreciation SaleLeasebackTransactionAccumulatedDepreciation	1091000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1947000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2074000	USD
CY2021Q2	us-gaap	Depreciation Depreciation	40000.00	USD
	us-gaap	Depreciation Depreciation	90000.00	USD
CY2020Q2	us-gaap	Depreciation Depreciation	50000.00	USD
	us-gaap	Depreciation Depreciation	10000.00	USD
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	200000	USD
CY2021Q2	curr	Current Portion Of Note Receivable Net CurrentPortionOfNoteReceivableNet	0	USD
CY2020Q4	curr	Current Portion Of Note Receivable Net CurrentPortionOfNoteReceivableNet	0	USD
CY2021Q2	us-gaap	Notes Receivable Gross NotesReceivableGross	200000	USD
CY2020Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	0	USD
CY2019	curr	Patents Received From Acquisition Of Chemistry Holdings Inc PatentsReceivedFromAcquisitionOfChemistryHoldingsInc	700000	USD
CY2019	curr	Inprocess Research And Development Received From Acquisition Of Chemistry Holdings Inc InprocessResearchAndDevelopmentReceivedFromAcquisitionOfChemistryHoldingsInc	14500000	USD
CY2021Q2	us-gaap	Goodwill Gross GoodwillGross	13868000	USD
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	13868000	USD
CY2021Q2	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	7110000	USD
CY2020Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	7110000	USD
CY2020Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	26917000	USD
CY2021Q2	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	2787000	USD
CY2020Q4	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	1312000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	24188000	USD
CY2020	curr	Interest Rate InterestRate	0.01	pure
	curr	Royalty Revenues RoyaltyRevenues	300000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19822000	USD
CY2021Q2	curr	Accounts Payable Factoring AccountsPayableFactoring	1851000	USD
CY2020Q4	curr	Accounts Payable Factoring AccountsPayableFactoring	0	USD
CY2021Q2	curr	Refunds And Returns Liability RefundsAndReturnsLiability	356000	USD
CY2020Q4	curr	Refunds And Returns Liability RefundsAndReturnsLiability	0	USD
CY2021Q2	curr	Accrued Interest AccruedInterest	325000	USD
CY2020Q4	curr	Accrued Interest AccruedInterest	194000	USD
CY2021Q2	curr	Accrued Payroll AccruedPayroll	272000	USD
CY2020Q4	curr	Accrued Payroll AccruedPayroll	308000	USD
CY2021Q2	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	248000	USD
CY2020Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	180000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	310000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	306000	USD
CY2021Q2	curr	Sales Tax Payable SalesTaxPayable	346000	USD
CY2020Q4	curr	Sales Tax Payable SalesTaxPayable	311000	USD
CY2021Q2	curr	Accrued Expenses Net AccruedExpensesNet	3708000	USD
CY2020Q4	curr	Accrued Expenses Net AccruedExpensesNet	1299000	USD
CY2020Q4	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	300000	USD
CY2021Q2	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	200000	USD
CY2021Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	20000.00	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	40000.00	USD
	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Company determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <em>Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</em>, then in accordance with ASC 815-40, <em>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</em>. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, the Company also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. The Company does not have any liability classified warrants as of any period presented.</p>
	curr	Contingencies Contingencies	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">We are exposed to claims and litigation arising in the ordinary course of business and use various methods to resolve these matters in a manner that we believe serves the best interest of our shareholders and other constituents. When a loss is probable, we record an accrual based on the reasonably estimable loss or range of loss. When no point of loss is more likely than another, we record the lowest amount in the estimated range of loss and, if material, disclose the estimated range of loss. We do not record liabilities for reasonably possible loss contingencies, but do disclose a range of reasonably possible losses if they are material and we are able to estimate such a range. If we cannot provide a range of reasonably possible losses, we explain the factors that prevent us from determining such a range. Historically, adjustments to our estimates have not been material. We believe the recorded reserves in our consolidated financial statements are adequate in light of the probable and estimable liabilities. We do not believe that any of these identified claims or litigation will be material to our results of operations, cash flows, or financial condition.</p>
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4572000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-11392000	USD
	curr	Common Stock And Common Stock Equivalents CommonStockAndCommonStockEquivalents	39867063000	shares
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.32
CY2020Q4	curr	Convertible Promissory Notes ConvertiblePromissoryNotes	550000	USD
CY2021Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	550000	USD
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	550000	USD
CY2020Q4	curr	Current Portion Of Loan Payable CurrentPortionOfLoanPayable	-265000	USD
CY2021Q2	curr	Loan Payable Less Current Portion LoanPayableLessCurrentPortion	0	USD
CY2020Q4	curr	Loan Payable Less Current Portion LoanPayableLessCurrentPortion	0	USD
CY2021Q2	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1000.000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	3000.000	USD
CY2020Q2	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1000.000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2000.000	USD
CY2021Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1550000	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	800000	USD
CY2021Q1	curr	Gross Proceeds Net GrossProceedsNet	1000000.0	USD
CY2021Q2	curr	Payment Protection Program Loan PaymentProtectionProgramLoan	0	USD
CY2020Q4	curr	Payment Protection Program Loan PaymentProtectionProgramLoan	605000	USD
CY2021Q2	us-gaap	Commercial Paper CommercialPaper	16510000	USD
CY2020Q4	us-gaap	Commercial Paper CommercialPaper	18684000	USD
CY2021Q2	curr	Less Investor Note Offset LessInvestorNoteOffset	-5000000	USD
CY2020Q4	curr	Less Investor Note Offset LessInvestorNoteOffset	-5000000	USD
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	11510000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	13684000	USD
CY2021Q2	curr	Less Current Portion Of Convertible Promissory Notes At Fair Value LessCurrentPortionOfConvertiblePromissoryNotesAtFairValue	-7221000	USD
CY2020Q4	curr	Less Current Portion Of Convertible Promissory Notes At Fair Value LessCurrentPortionOfConvertiblePromissoryNotesAtFairValue	-6674000	USD
CY2021Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	4289000	USD
CY2021Q2	us-gaap	Convertible Subordinated Debt ConvertibleSubordinatedDebt	12221000	USD
CY2020Q4	us-gaap	Convertible Subordinated Debt ConvertibleSubordinatedDebt	11674000	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	7010000	USD

CY2021Q3

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

62877959

shares

CY2021Q2

us-gaap

Cash

1701000

USD

CY2020Q4

us-gaap

Cash

1725000

USD

CY2021Q2

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

242000

USD

CY2020Q4

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

224000

USD

CY2021Q2

us-gaap

Notes Receivable Net

NotesReceivableNet

0

USD

CY2020Q4

us-gaap

Notes Receivable Net

NotesReceivableNet

0

USD

CY2021Q2

us-gaap

Inventory Net

InventoryNet

831000

USD

CY2020Q4

us-gaap

Inventory Net

InventoryNet

449000

USD

CY2021Q2

us-gaap

Prepaid Expense And Other Assets Current

PrepaidExpenseAndOtherAssetsCurrent

516000

USD

CY2020Q4

us-gaap

Prepaid Expense And Other Assets Current

PrepaidExpenseAndOtherAssetsCurrent

1452000

USD

CY2021Q2

us-gaap

Assets Current

AssetsCurrent

3290000

USD

CY2020Q4

us-gaap

Assets Current

AssetsCurrent

3850000

USD

CY2021Q2

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

1947000

USD

CY2020Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

2074000

USD

CY2021Q2

us-gaap

Finance Lease Right Of Use Asset

FinanceLeaseRightOfUseAsset

46000

USD

CY2021Q2

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

242000

USD

CY2021Q2

us-gaap

Inventory Net

InventoryNet

831000

USD

CY2020Q4

us-gaap

Finance Lease Right Of Use Asset

FinanceLeaseRightOfUseAsset

52000

USD

CY2021Q2

us-gaap

Operating Lease Right Of Use Asset

OperatingLeaseRightOfUseAsset

301000

USD

CY2020Q4

us-gaap

Operating Lease Right Of Use Asset

OperatingLeaseRightOfUseAsset

343000

USD

CY2021Q2

us-gaap

Notes And Loans Receivable Net Noncurrent

NotesAndLoansReceivableNetNoncurrent

200000

USD

CY2020Q4

us-gaap

Notes And Loans Receivable Net Noncurrent

NotesAndLoansReceivableNetNoncurrent

0

USD

CY2021Q2

us-gaap

Investments

509000

USD

CY2020Q4

us-gaap

Investments

509000

USD

CY2021Q2

us-gaap

Goodwill

13868000

USD

CY2020Q4

us-gaap

Goodwill

13868000

USD

CY2021Q2

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

11869000

USD

CY2020Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

1711000

USD

CY2021Q2

us-gaap

Deferred Tax Assets In Process Research And Development

DeferredTaxAssetsInProcessResearchAndDevelopment

3867000

USD

CY2020Q4

us-gaap

Deferred Tax Assets In Process Research And Development

DeferredTaxAssetsInProcessResearchAndDevelopment

14288000

USD

CY2021Q2

curr

Customer Relationships Tradename And Non Compete Net

CustomerRelationshipsTradenameAndNonCompeteNet

8452000

USD

CY2020Q4

curr

Customer Relationships Tradename And Non Compete Net

CustomerRelationshipsTradenameAndNonCompeteNet

9606000

USD

CY2021Q2

us-gaap

Other Assets

OtherAssets

83000

USD

CY2020Q4

us-gaap

Other Assets

OtherAssets

58000

USD

CY2021Q2

us-gaap

Assets

44432000

USD

CY2020Q4

us-gaap

Assets

46359000

USD

CY2021Q2

us-gaap

Accounts Payable Current

AccountsPayableCurrent

2015000

USD

CY2020Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

2135000

USD

CY2021Q2

curr

Accrued Expenses Net

AccruedExpensesNet

3708000

USD

CY2020Q4

curr

Accrued Expenses Net

AccruedExpensesNet

1299000

USD

CY2021Q2

us-gaap

Finance Lease Liability

FinanceLeaseLiability

12000

USD

CY2020Q4

us-gaap

Finance Lease Liability

FinanceLeaseLiability

12000

USD

CY2021Q2

us-gaap

Operating Lease Liability Current

OperatingLeaseLiabilityCurrent

100000

USD

CY2020Q4

us-gaap

Operating Lease Liability Current

OperatingLeaseLiabilityCurrent

93000

USD

CY2021Q2

us-gaap

Loans Payable

LoansPayable

46000

USD

CY2020Q4

us-gaap

Loans Payable

LoansPayable

265000

USD

CY2021Q2

us-gaap

Program Rights Obligations

ProgramRightsObligations

0

USD

CY2020Q4

us-gaap

Program Rights Obligations

ProgramRightsObligations

605000

USD

CY2021Q2

us-gaap

Due To Related Parties Current

DueToRelatedPartiesCurrent

1240000

USD

CY2020Q4

us-gaap

Due To Related Parties Current

DueToRelatedPartiesCurrent

1040000

USD

CY2021Q2

us-gaap

Notes Payable Current

NotesPayableCurrent

1550000

USD

CY2020Q4

us-gaap

Notes Payable Current

NotesPayableCurrent

800000

USD

CY2021Q2

us-gaap

Convertible Notes Payable Current

ConvertibleNotesPayableCurrent

550000

USD

CY2020Q4

us-gaap

Convertible Notes Payable Current

ConvertibleNotesPayableCurrent

550000

USD

CY2021Q2

us-gaap

Convertible Long Term Notes Payable

ConvertibleLongTermNotesPayable

7221000

USD

CY2020Q4

us-gaap

Convertible Long Term Notes Payable

ConvertibleLongTermNotesPayable

6674000

USD

CY2021Q2

us-gaap

Deposit Contracts Liabilities

DepositContractsLiabilities

597000

USD

CY2020Q4

us-gaap

Deposit Contracts Liabilities

DepositContractsLiabilities

994000

USD

CY2021Q2

us-gaap

Liabilities Current

LiabilitiesCurrent

17039000

USD

CY2020Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

14467000

USD

CY2021Q2

curr

License Fees

LicenseFees

0

USD

CY2020Q4

curr

License Fees

LicenseFees

80000

USD

CY2021Q2

curr

Finance Lease Payable

FinanceLeasePayable

34000

USD

CY2020Q4

curr

Finance Lease Payable

FinanceLeasePayable

40000

USD

CY2021Q2

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

227000

USD

CY2020Q4

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

278000

USD

CY2021Q2

curr

Fair Value Convertible Promissory Notes Nets

FairValueConvertiblePromissoryNotesNets

4289000

USD

CY2020Q4

curr

Fair Value Convertible Promissory Notes Nets

FairValueConvertiblePromissoryNotesNets

7010000

USD

CY2021Q2

us-gaap

Contingent Consideration Classified As Equity Fair Value Disclosure

ContingentConsiderationClassifiedAsEquityFairValueDisclosure

1650000

USD

CY2020Q4

us-gaap

Contingent Consideration Classified As Equity Fair Value Disclosure

ContingentConsiderationClassifiedAsEquityFairValueDisclosure

3205000

USD

CY2021Q2

us-gaap

Liabilities

23239000

USD

CY2020Q4

us-gaap

Liabilities

25080000

USD

CY2021Q2

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2021Q2

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

150000000

shares

CY2021Q2

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

62877959

shares

CY2020Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

59476268

shares

CY2021Q2

us-gaap

Common Stock Value

CommonStockValue

63000

USD

CY2020Q4

us-gaap

Common Stock Value

CommonStockValue

60000

USD

CY2021Q2

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

106272000

USD

CY2020Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

101807000

USD

CY2021Q2

us-gaap

Common Unit Issuance Value

CommonUnitIssuanceValue

603000

USD

CY2020Q4

us-gaap

Common Unit Issuance Value

CommonUnitIssuanceValue

665000

USD

CY2021Q2

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-85745000

USD

CY2020Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-81253000

USD

CY2021Q2

us-gaap

Stockholders Equity

StockholdersEquity

21193000

USD

CY2020Q4

us-gaap

Stockholders Equity

StockholdersEquity

21279000

USD

CY2021Q2

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

44432000

USD

CY2020Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

46359000

USD

CY2021Q2

curr

Product Sales Net Of Discounts And Refunds

ProductSalesNetOfDiscountsAndRefunds

2066000

USD

CY2020Q2

curr

Product Sales Net Of Discounts And Refunds

ProductSalesNetOfDiscountsAndRefunds

163000

USD

curr

Product Sales Net Of Discounts And Refunds

ProductSalesNetOfDiscountsAndRefunds

3447000

USD

curr

Product Sales Net Of Discounts And Refunds

ProductSalesNetOfDiscountsAndRefunds

366000

USD

CY2021Q2

us-gaap

Other Income

OtherIncome

25000

USD

CY2020Q2

us-gaap

Other Income

OtherIncome

100000

USD

us-gaap

Other Income

OtherIncome

52000

USD

us-gaap

Other Income

OtherIncome

169000

USD

CY2021Q2

curr

Shipping And Other Sales

ShippingAndOtherSales

18000

USD

CY2020Q2

curr

Shipping And Other Sales

ShippingAndOtherSales

6000

USD

curr

Shipping And Other Sales

ShippingAndOtherSales

56000

USD

curr

Shipping And Other Sales

ShippingAndOtherSales

14000

USD

CY2021Q2

us-gaap

Revenues

2109000

USD

CY2020Q2

us-gaap

Revenues

269000

USD

us-gaap

Revenues

3555000

USD

us-gaap

Revenues

549000

USD

CY2021Q2

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

797000

USD

CY2020Q2

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

100000

USD

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

1214000

USD

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

201000

USD

CY2021Q2

us-gaap

Gross Profit

GrossProfit

1312000

USD

CY2020Q2

us-gaap

Gross Profit

GrossProfit

169000

USD

us-gaap

Gross Profit

GrossProfit

2341000

USD

us-gaap

Gross Profit

GrossProfit

348000

USD

CY2021Q2

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

699000

USD

CY2020Q2

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

735000

USD

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

1343000

USD

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

1540000

USD

CY2021Q2

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

4772000

USD

CY2020Q2

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

2511000

USD

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

10316000

USD

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

4635000

USD

CY2021Q2

curr

Change In Fair Value Of Contingent Stock Consideration

ChangeInFairValueOfContingentStockConsideration

-894000

USD

CY2020Q2

curr

Change In Fair Value Of Contingent Stock Consideration

ChangeInFairValueOfContingentStockConsideration

10390000

USD

curr

Change In Fair Value Of Contingent Stock Consideration

ChangeInFairValueOfContingentStockConsideration

-1555000

USD

curr

Change In Fair Value Of Contingent Stock Consideration

ChangeInFairValueOfContingentStockConsideration

5658000

USD

CY2021Q2

us-gaap

Operating Expenses

OperatingExpenses

4577000

USD

CY2020Q2

us-gaap

Operating Expenses

OperatingExpenses

13636000

USD

us-gaap

Operating Expenses

OperatingExpenses

10104000

USD

us-gaap

Operating Expenses

OperatingExpenses

11833000

USD

CY2021Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

-3265000

USD

CY2020Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

-13467000

USD

us-gaap

Operating Income Loss

OperatingIncomeLoss

-7763000

USD

us-gaap

Operating Income Loss

OperatingIncomeLoss

-11485000

USD

CY2021Q2

us-gaap

Interest Income Operating

InterestIncomeOperating

1000

USD

CY2020Q2

us-gaap

Interest Income Operating

InterestIncomeOperating

5000

USD

us-gaap

Interest Income Operating

InterestIncomeOperating

2000

USD

us-gaap

Interest Income Operating

InterestIncomeOperating

20000

USD

CY2021Q2

us-gaap

Gain Loss Related To Litigation Settlement

GainLossRelatedToLitigationSettlement

2434000

USD

CY2020Q2

us-gaap

Gain Loss Related To Litigation Settlement

GainLossRelatedToLitigationSettlement

26000

USD

us-gaap

Gain Loss Related To Litigation Settlement

GainLossRelatedToLitigationSettlement

2434000

USD

us-gaap

Gain Loss Related To Litigation Settlement

GainLossRelatedToLitigationSettlement

26000

USD

CY2021Q2

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

335000

USD

CY2020Q2

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

0

USD

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

734000

USD

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

0

USD

CY2021Q2

us-gaap

Gain Loss On Sale Of Property Plant Equipment

GainLossOnSaleOfPropertyPlantEquipment

0

USD

CY2020Q2

us-gaap

Gain Loss On Sale Of Property Plant Equipment

GainLossOnSaleOfPropertyPlantEquipment

0

USD

us-gaap

Gain Loss On Sale Of Property Plant Equipment

GainLossOnSaleOfPropertyPlantEquipment

-41000

USD

us-gaap

Gain Loss On Sale Of Property Plant Equipment

GainLossOnSaleOfPropertyPlantEquipment

0

USD

CY2021Q2

us-gaap

Increase Decrease In Derivative Assets And Liabilities

IncreaseDecreaseInDerivativeAssetsAndLiabilities

0

USD

CY2020Q2

us-gaap

Increase Decrease In Derivative Assets And Liabilities

IncreaseDecreaseInDerivativeAssetsAndLiabilities

12000

USD

us-gaap

Increase Decrease In Derivative Assets And Liabilities

IncreaseDecreaseInDerivativeAssetsAndLiabilities

0

USD

us-gaap

Increase Decrease In Derivative Assets And Liabilities

IncreaseDecreaseInDerivativeAssetsAndLiabilities

75000

USD

CY2021Q2

curr

Change In Fair Value Of Convertible Promissory Notes

ChangeInFairValueOfConvertiblePromissoryNotes

-692000

USD

CY2020Q2

curr

Change In Fair Value Of Convertible Promissory Notes

ChangeInFairValueOfConvertiblePromissoryNotes

0

USD

curr

Change In Fair Value Of Convertible Promissory Notes

ChangeInFairValueOfConvertiblePromissoryNotes

340000

USD

curr

Change In Fair Value Of Convertible Promissory Notes

ChangeInFairValueOfConvertiblePromissoryNotes

0

USD

CY2021Q2

us-gaap

Interest Expense Other

InterestExpenseOther

134000

USD

CY2020Q2

us-gaap

Interest Expense Other

InterestExpenseOther

15000

USD

us-gaap

Interest Expense Other

InterestExpenseOther

199000

USD

us-gaap

Interest Expense Other

InterestExpenseOther

28000

USD

CY2021Q2

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

1944000

USD

CY2020Q2

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

28000

USD

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

3270000

USD

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

93000

USD

CY2021Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-1321000

USD

CY2020Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-13439000

USD

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-4493000

USD

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-11392000

USD

CY2021Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

0

USD

CY2020Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

0

USD

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

0

USD

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

0

USD

CY2021Q2

us-gaap

Net Income Loss

NetIncomeLoss

-1321000

USD

CY2020Q2

us-gaap

Net Income Loss

NetIncomeLoss

-13439000

USD

us-gaap

Net Income Loss

NetIncomeLoss

-4493000

USD

us-gaap

Net Income Loss

NetIncomeLoss

-11392000

USD

CY2021Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-0.02

CY2020Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-0.32

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-0.09

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-0.29

CY2021Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-0.02

CY2020Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-0.32

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-0.09

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-0.29

CY2021Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

59842904

shares

CY2020Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

41716558

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

48299751

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

39867063

shares

CY2021Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

59842904

shares

CY2020Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

41716558

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

48299751

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

39867063

shares

CY2020Q4

us-gaap

Stockholders Equity

StockholdersEquity

21279000

USD

CY2021Q1

curr

Issuance Of Common Stock For Professional Services Amount

IssuanceOfCommonStockForProfessionalServicesAmount

508000

USD

CY2021Q1

curr

Issuance Of Common Stock From The Equity Incentive Plan Amount

IssuanceOfCommonStockFromTheEquityIncentivePlanAmount

138000

USD

CY2021Q1

curr

Issuance Of Common Stock For Exercise Of Warrants Amount

IssuanceOfCommonStockForExerciseOfWarrantsAmount

0

USD

CY2021Q1

curr

Fair Value Of Stock Options And Restricted Stock Granted

FairValueOfStockOptionsAndRestrictedStockGranted

961000

USD

CY2021Q1

curr

Fair Value Of Restricted Stock Units Granted

FairValueOfRestrictedStockUnitsGranted

144000

USD

CY2021Q1

us-gaap

Net Income Loss

NetIncomeLoss

-3171000

USD

CY2021Q1

us-gaap

Stockholders Equity

StockholdersEquity

19859000

USD

CY2021Q2

curr

Issuance Of Common Stock For Professional Services Amount

IssuanceOfCommonStockForProfessionalServicesAmount

243000

USD

CY2021Q2

curr

Issuance Of Common Stock From The Equity Incentive Plan Amount

IssuanceOfCommonStockFromTheEquityIncentivePlanAmount

-157000

USD

CY2021Q2

curr

Issuance Of Common Stock From Conversion Of Convertible Promissory Notes Amount

IssuanceOfCommonStockFromConversionOfConvertiblePromissoryNotesAmount

1835000

USD

CY2021Q2

curr

Fair Value Of Stock Options And Restricted Stock Granted

FairValueOfStockOptionsAndRestrictedStockGranted

591000

USD

CY2021Q2

curr

Fair Value Of Restricted Stock Units Granted

FairValueOfRestrictedStockUnitsGranted

143000

USD

CY2021Q2

us-gaap

Net Income Loss

NetIncomeLoss

-1321000

USD

CY2021Q2

us-gaap

Stockholders Equity

StockholdersEquity

21193000

USD

CY2019Q4

us-gaap

Stockholders Equity

StockholdersEquity

13507000

USD

CY2020Q1

curr

Issuance Of Common Stock For Professional Services Amount

IssuanceOfCommonStockForProfessionalServicesAmount

231000

USD

CY2020Q1

curr

Fair Value Of Stock Options And Restricted Stock Granted

FairValueOfStockOptionsAndRestrictedStockGranted

469000

USD

CY2020Q1

curr

Fair Value Of Restricted Stock Units Granted

FairValueOfRestrictedStockUnitsGranted

60000

USD

CY2020Q1

us-gaap

Net Income Loss

NetIncomeLoss

2046000

USD

CY2020Q1

us-gaap

Stockholders Equity

StockholdersEquity

16313000

USD

CY2020Q2

curr

Issuance Of Common Stock For Professional Services Amount

IssuanceOfCommonStockForProfessionalServicesAmount

189000

USD

CY2020Q2

curr

Issuance Of Common Stock From The Equity Incentive Plan Amount

IssuanceOfCommonStockFromTheEquityIncentivePlanAmount

0

USD

CY2020Q2

curr

Issuance Of Common Stock From Exercise Of Warrants Amount

IssuanceOfCommonStockFromExerciseOfWarrantsAmount

1418000

USD

CY2020Q2

curr

Issuance Of Common Stock From Settlement With Chemistry Holdings Inc Amount

IssuanceOfCommonStockFromSettlementWithChemistryHoldingsIncAmount

21701000

USD

CY2020Q2

curr

Fair Value Of Stock Options And Restricted Stock Granted

FairValueOfStockOptionsAndRestrictedStockGranted

479000

USD

CY2020Q2

curr

Fair Value Of Restricted Stock Units Granted

FairValueOfRestrictedStockUnitsGranted

60000

USD

CY2020Q2

us-gaap

Net Income Loss

NetIncomeLoss

-13439000

USD

CY2020Q2

us-gaap

Stockholders Equity

StockholdersEquity

26721000

USD

us-gaap

Net Income Loss

NetIncomeLoss

-4493000

USD

us-gaap

Net Income Loss

NetIncomeLoss

-11392000

USD

us-gaap

Issuance Of Stock And Warrants For Services Or Claims

IssuanceOfStockAndWarrantsForServicesOrClaims

752000

USD

us-gaap

Issuance Of Stock And Warrants For Services Or Claims

IssuanceOfStockAndWarrantsForServicesOrClaims

420000

USD

us-gaap

Stock Granted During Period Value Sharebased Compensation Gross

StockGrantedDuringPeriodValueSharebasedCompensationGross

0

USD

us-gaap

Stock Granted During Period Value Sharebased Compensation Gross

StockGrantedDuringPeriodValueSharebasedCompensationGross

300000

USD

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

19000

USD

us-gaap

Property Plant And Equipment Disposals

PropertyPlantAndEquipmentDisposals

0

USD

us-gaap

Proceeds From Sale And Collection Of Notes Receivable

ProceedsFromSaleAndCollectionOfNotesReceivable

0

USD

curr

Gain From Settlement Of Accounts Payable

GainFromSettlementOfAccountsPayable

26000

USD

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

734000

USD

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

0

USD

us-gaap

Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1

BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1

-1555000

USD

us-gaap

Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1

BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1

5658000

USD

curr

Change In Fair Value Of Convertible Promissory Notes

ChangeInFairValueOfConvertiblePromissoryNotes

340000

USD

us-gaap

Payments To Acquire Intangible Assets

PaymentsToAcquireIntangibleAssets

8000

USD

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

32000

USD

us-gaap

Proceeds From Related Party Debt

ProceedsFromRelatedPartyDebt

0

USD

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

1578000

USD

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

164000

USD

us-gaap

Finance Lease Right Of Use Asset Amortization

FinanceLeaseRightOfUseAssetAmortization

48000

USD

us-gaap

Finance Lease Right Of Use Asset Amortization

FinanceLeaseRightOfUseAssetAmortization

6000

USD

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

586000

USD

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

25000

USD

curr

Common Stock Issued For Settlement Of Earnout Liabilities From The Acquisition Of Chemistry Holdings Inc

CommonStockIssuedForSettlementOfEarnoutLiabilitiesFromTheAcquisitionOfChemistryHoldingsInc

0

USD

us-gaap

Increase Decrease In Notes Receivable Current

IncreaseDecreaseInNotesReceivableCurrent

200000

USD

us-gaap

Proceeds From Sale And Collection Of Notes Receivable

ProceedsFromSaleAndCollectionOfNotesReceivable

200000

USD

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-99000

USD

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-844000

USD

us-gaap

Proceeds From Warrant Exercises

ProceedsFromWarrantExercises

1417000

USD

us-gaap

Proceeds From Notes Payable

ProceedsFromNotesPayable

750000

USD

CY2021Q2

curr

Accumulated Deficits

AccumulatedDeficits

-13700000

USD

CY2021Q2

us-gaap

Allowance For Doubtful Accounts Receivable Current

AllowanceForDoubtfulAccountsReceivableCurrent

80000.00

USD

CY2020Q4

us-gaap

Allowance For Doubtful Accounts Receivable Current

AllowanceForDoubtfulAccountsReceivableCurrent

40000.00

USD

us-gaap

Allowance For Loan And Lease Loss Recovery Of Bad Debts

AllowanceForLoanAndLeaseLossRecoveryOfBadDebts

41000

USD

us-gaap

Allowance For Loan And Lease Loss Recovery Of Bad Debts

AllowanceForLoanAndLeaseLossRecoveryOfBadDebts

14000

USD

curr

Recovery Of Bad Debt Expense

RecoveryOfBadDebtExpense

221000

USD

us-gaap

Income Taxes Paid Net

IncomeTaxesPaidNet

0

USD

us-gaap

Property Plant And Equipment Disposals

PropertyPlantAndEquipmentDisposals

41000

USD

us-gaap

Income Taxes Paid Net

IncomeTaxesPaidNet

0

USD

curr

Inventory Reserve For Obsolescence

InventoryReserveForObsolescence

109000

USD

curr

Inventory Reserve For Obsolescence

InventoryReserveForObsolescence

2000

USD

curr

Common Stock Issued For Conversion Of Promissory Notes And Accrued Interest

CommonStockIssuedForConversionOfPromissoryNotesAndAccruedInterest

0

USD

us-gaap

Increase Decrease In Derivative Liabilities

IncreaseDecreaseInDerivativeLiabilities

75000

USD

curr

Fair Value Of Vested Stock Options And Restricted Stock

FairValueOfVestedStockOptionsAndRestrictedStock

1839000

USD

curr

Fair Value Of Vested Stock Options And Restricted Stock

FairValueOfVestedStockOptionsAndRestrictedStock

1069000

USD

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

-59000

USD

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

85000

USD

us-gaap

Increase Decrease In Inventories

IncreaseDecreaseInInventories

273000

USD

us-gaap

Increase Decrease In Inventories

IncreaseDecreaseInInventories

52000

USD

us-gaap

Increase Decrease In Prepaid Expenses Other

IncreaseDecreaseInPrepaidExpensesOther

957000

USD

us-gaap

Increase Decrease In Prepaid Expenses Other

IncreaseDecreaseInPrepaidExpensesOther

-36000

USD

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

-95000

USD

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

139000

USD

us-gaap

Increase Decrease In Accrued Liabilities

IncreaseDecreaseInAccruedLiabilities

2538000

USD

us-gaap

Increase Decrease In Accrued Liabilities

IncreaseDecreaseInAccruedLiabilities

113000

USD

us-gaap

Increase Decrease In Other Noncurrent Liabilities

IncreaseDecreaseInOtherNoncurrentLiabilities

-6000

USD

us-gaap

Increase Decrease In Other Noncurrent Liabilities

IncreaseDecreaseInOtherNoncurrentLiabilities

-6000

USD

us-gaap

Operating Lease Payments

OperatingLeasePayments

44000

USD

us-gaap

Operating Lease Payments

OperatingLeasePayments

0

USD

us-gaap

Increase Decrease In Contract With Customer Liability

IncreaseDecreaseInContractWithCustomerLiability

-397000

USD

us-gaap

Increase Decrease In Contract With Customer Liability

IncreaseDecreaseInContractWithCustomerLiability

-152000

USD

us-gaap

Taxes And Licenses

TaxesAndLicenses

80000

USD

us-gaap

Taxes And Licenses

TaxesAndLicenses

5000

USD

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-656000

USD

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-3778000

USD

us-gaap

Investment Income Nonoperating

InvestmentIncomeNonoperating

0

USD

us-gaap

Investment Income Nonoperating

InvestmentIncomeNonoperating

250000

USD

us-gaap

Payments To Acquire Intangible Assets

PaymentsToAcquireIntangibleAssets

67000

USD

us-gaap

Proceeds From Notes Payable

ProceedsFromNotesPayable

649000

USD

us-gaap

Proceeds From Related Party Debt

ProceedsFromRelatedPartyDebt

200000

USD

us-gaap

Repayments Of Debt

RepaymentsOfDebt

219000

USD

us-gaap

Repayments Of Debt

RepaymentsOfDebt

111000

USD

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

731000

USD

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

1955000

USD

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

-24000

USD

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

-2667000

USD

CY2020Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

1725000

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4096000

USD

CY2021Q2

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

1701000

USD

CY2020Q2

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

1429000

USD

CY2020Q4

us-gaap

Deferred Revenue

DeferredRevenue

1000000.0

USD

CY2021Q2

curr

Customer Deposits For Commercial Products

CustomerDepositsForCommercialProducts

597000

USD

CY2020Q4

curr

Customer Deposits For Commercial Products

CustomerDepositsForCommercialProducts

281000

USD

CY2021Q2

curr

Customer Deposits For Personal Protective Equipment

CustomerDepositsForPersonalProtectiveEquipment

0

USD

CY2020Q4

curr

Customer Deposits For Personal Protective Equipment

CustomerDepositsForPersonalProtectiveEquipment

713000

USD

CY2021Q2

us-gaap

Deposit Contracts Liabilities

DepositContractsLiabilities

597000

USD

CY2020Q4

us-gaap

Deposit Contracts Liabilities

DepositContractsLiabilities

994000

USD

CY2020

curr

Contract Liabilities Beginning Balance

ContractLiabilitiesBeginningBalance

456000

USD

CY2020

curr

Additions To Contract Liabilities

AdditionsToContractLiabilities

1033000

USD

CY2020

curr

Transfers To Revenue

TransfersToRevenue

-495000

USD

curr

Additions To Contract Liabilities

AdditionsToContractLiabilities

591000

USD

curr

Customer Deposits Returned

CustomerDepositsReturned

-713000

USD

curr

Transfers To Revenue

TransfersToRevenue

-275000

USD

curr

Contract Liabilities Ending Balance

ContractLiabilitiesEndingBalance

597000

USD

us-gaap

Advertising Expense

AdvertisingExpense

1000000.0

USD

CY2020Q2

curr

Research And Development Expenses

ResearchAndDevelopmentExpenses

700000

USD

curr

Research And Development Expenses

ResearchAndDevelopmentExpenses

1500000

USD

CY2021Q2

curr

Valuation Allowance Percentage

ValuationAllowancePercentage

1

pure

CY2020Q4

us-gaap

Business Combination Contingent Consideration Liability

BusinessCombinationContingentConsiderationLiability

3200000

USD

curr

Notes Payable Fair Value

NotesPayableFairValue

18684

USD

curr

Changes In Fair Value Of Series A Note

ChangesInFairValueOfSeriesANote

-886000

USD

curr

Change In Fair Value Of Series B Notes

ChangeInFairValueOfSeriesBNotes

546000

USD

curr

Conversion Of Series A Notes

ConversionOfSeriesANotes

-1834000

USD

curr

Fair Value Of Series A And B Notes

FairValueOfSeriesAAndBNotes

16510

USD

curr

Conversion Price

ConversionPrice

0.51

CY2020

curr

Stock Price

StockPrice

1.30

curr

Stock Price

StockPrice

1.32

CY2020

curr

Conversion Price

ConversionPrice

1.32

curr

Interest Rate

InterestRate

0.18

pure

CY2021Q2

us-gaap

Servicing Asset At Fair Value Other Changes In Fair Value

ServicingAssetAtFairValueOtherChangesInFairValue

700000

USD

CY2021Q2

us-gaap

Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest

IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

-1400000

USD

CY2020Q2

us-gaap

Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest

IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

-13439000

USD

us-gaap

Interest Paid Net

InterestPaidNet

68000

USD

us-gaap

Interest Paid Net

InterestPaidNet

3000

USD

curr

Common Stock Issued For Conversion Of Promissory Notes And Accrued Interest

CommonStockIssuedForConversionOfPromissoryNotesAndAccruedInterest

1834000

USD

curr

Common Stock Issued For Settlement Of Earnout Liabilities From The Acquisition Of Chemistry Holdings Inc

CommonStockIssuedForSettlementOfEarnoutLiabilitiesFromTheAcquisitionOfChemistryHoldingsInc

21701000

USD

us-gaap

Basis Of Accounting

BasisOfAccounting

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by GAAP for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of June 30, 2021, and the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2021 and 2020, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in Form 10-K for the fiscal period ended December 31, 2020 filed with the SEC on March 31, 2021.

CY2021Q2

curr

Working Capital Deficit

WorkingCapitalDeficit

-85800000

USD

CY2021Q2

us-gaap

Cash Equivalents At Carrying Value

CashEquivalentsAtCarryingValue

700000

USD

us-gaap

Payments For Brokerage Fees

PaymentsForBrokerageFees

700000

USD

CY2021Q2

us-gaap

Cash Equivalents At Carrying Value

CashEquivalentsAtCarryingValue

2300000

USD

us-gaap

Reclassifications

Certain reclassifications have been made to prior year’s consolidated financial statements to enhance comparability with the current year’s consolidated financial statements. These reclassifications had no effect on the previously reported net loss.

us-gaap

Use Of Estimates

UseOfEstimates

The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include, but are not limited to, the allowance for doubtful accounts, valuation of intangible assets and goodwill, depreciative and amortization useful lives, assumptions used to calculate the fair value of the contingent share consideration, stock based compensation, beneficial conversion features, warrant values, deferred taxes and the assumptions used to calculate derivative liabilities and fair values of the purchase price allocations and convertible promissory notes. Actual results could differ materially from such estimates under different assumptions or circumstances.

CY2021Q2

curr

Outstanding Shares Of Common Stock

OutstandingSharesOfCommonStock

20000000

shares

CY2021Q2

us-gaap

Weighted Average Number Of Share Outstanding Basic And Diluted

WeightedAverageNumberOfShareOutstandingBasicAndDiluted

59842904000

shares

CY2020Q2

us-gaap

Weighted Average Number Of Share Outstanding Basic And Diluted

WeightedAverageNumberOfShareOutstandingBasicAndDiluted

41716558000

shares

us-gaap

Weighted Average Number Of Share Outstanding Basic And Diluted

WeightedAverageNumberOfShareOutstandingBasicAndDiluted

48299751000

shares

us-gaap

Weighted Average Number Of Share Outstanding Basic And Diluted

WeightedAverageNumberOfShareOutstandingBasicAndDiluted

39867063000

shares

CY2021Q2

curr

Common Stock And Common Stock Equivalents

CommonStockAndCommonStockEquivalents

59842904000

shares

CY2020Q2

curr

Common Stock And Common Stock Equivalents

CommonStockAndCommonStockEquivalents

41716558000

shares

curr

Common Stock And Common Stock Equivalents

CommonStockAndCommonStockEquivalents

48299751000

shares

CY2021Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-0.02

CY2020Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-0.32

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-0.09

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-0.29

CY2021Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-0.02

CY2020Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-0.32

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-0.09

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-0.29

CY2021Q2

curr

Vested Stock Options From The Companys2017 Equity Incentive Plan

VestedStockOptionsFromTheCompanys2017EquityIncentivePlan

3471304

shares

curr

Vested Stock Options From The Companys2017 Equity Incentive Plan

VestedStockOptionsFromTheCompanys2017EquityIncentivePlan

3460767

shares

CY2021Q2

curr

Warrants Shares

WarrantsShares

2264091

shares

curr

Warrants Shares

WarrantsShares

6648446

shares

curr

Shares To Be Issued Upon Conversion Of Convertible Payable

SharesToBeIssuedUponConversionOfConvertiblePayable

115047

shares

CY2021Q2

curr

Shares To Be Issued Upon Conversion Of Convertible Payable

SharesToBeIssuedUponConversionOfConvertiblePayable

115047

shares

CY2021Q2

curr

Total Anti Dilutive Shares

TotalAntiDilutiveShares

5850442

shares

curr

Total Anti Dilutive Shares

TotalAntiDilutiveShares

10224260

shares

curr

Cost To Obtain A Contractpolicytextblock

CostToObtainAContractpolicytextblock

The Company pays sales commission to its employees and outside sales representatives for contracts that they obtain relating to wholesale and personal protective equipment. The Company applies the optional practical expedient to immediately expense costs to obtain a contract if the amortization period of the asset that would have been recognized is one year or less. As such, sales commissions are immediately recognized as an expense and included as part of sales and marketing expenses.

curr

Contingent Consideration Liabilitiespolicytextblock

ContingentConsiderationLiabilitiespolicytextblock

Certain of the Company’s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined upon attainment of revenue milestones, from product sales, as applicable. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration.ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of revenues generated from the Sera Labs’ products. The fair value of contingent consideration after the acquisition date is reassessed by the Company as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that the Company records in its consolidated financial statements. See Note 19 for a full discussion of these liabilities.

curr

Cure Pharmaceutical Revenuepolicytexkblock

CurePharmaceuticalRevenuepolicytexkblock

Cure Pharmaceutical derives revenues from two primary sources: products and services. Product revenue includes the shipment of products according to agreements with the Cure Pharmaceutical’s customers. Services include research and development contracts for the development of OTF products utilizing the Cure Pharmaceutical’s CureFilm Technology or our other proprietary technologies. Cure Pharmaceutical’s contracts with customers rarely contain multiple performance obligations. For these contracts, Cure Pharmaceutical accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Standalone selling prices are typically estimated based on observable transactions when these services are sold on a standalone basis. Cure Pharmaceutical’s formulation and product development income include services for the development of OTF products utilizing our CureFilm Technology. Our development contracts can have up to four phases. Revenue is recognized based on progress toward completion of the performance obligation in each phase. The method to measure progress toward completion requires judgment and is based on the nature of the products or services to be provided. Cure Pharmaceutical generally uses the input method to measure progress for its contracts because it best depicts the transfer of assets to the customer, which occurs as we incur costs for the contracts. Under the cost-to-cost measure of progress, the progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. Revenue is recorded proportionally as costs are incurred. Costs to fulfill these obligations mainly include materials, labor, supplies and consultants.Cure Pharmaceutical has entered into a Collaboration and Joint Development Agreement (“Agreement”) with Medolife Rx (“Medolife”) on February 1, 2021 (“Effective Date”) for Medolife to produce Medolife Products (“Products”) in Cure Pharmaceutical’s cGMP facility. The term of this agreement is for five (5) years from the Effective Date (“Term”). Medolife is to pay $0.3 million to assist in completing the jointly developed production line at Cure Pharmaceutical’s cGMP facility. In addition, Cure Pharmaceutical will produce Products on behalf of Medolife and will grant access to Medolife for a joint production area within Cure Pharmaceutical’s production facility for the Term of this Agreement. The Company has determined that there are no distinct obligations for the $0.3 million and Cure Pharmaceutical does have further obligations as stated in the Agreement, thus the Company will recognize the revenue monthly over the Term, beginning February 1, 2021.

CY2020Q4

us-gaap

Debt Instrument Periodic Payment Principal

DebtInstrumentPeriodicPaymentPrincipal

300000

USD

curr

Sera Labs Revenuepolicytexkblock

SeraLabsRevenuepolicytexkblock

Sera Labs recognizes revenue as, or when, we satisfy performance obligations under a contract. We account for a contract when the parties approved the contract and are committed to perform on it, the rights of each party and the payment terms are identified, the contract has commercial substance and it is probable that we will collect substantially all of the consideration. A performance obligation is a promise in a contract to transfer a distinct good or service, or a series of distinct goods or services, to a customer. The transaction price of a contract must be allocated to each performance obligation and recognized as the performance obligation is satisfied. In essence, we recognize revenue when or as control of the promised goods or services transfer to the customer. Revenue from eCommerce sales, including direct-to-consumer sales, are recognized upon shipment of merchandise. We also elected to adopt the practical expedient related to shipping and handling fees which allows us to account for shipping and handling activities that occur after control of the related good transfers as fulfillment activities instead of assessing such activities as performance obligations. Therefore, shipping and handling activities are considered part of the Company’s obligation to transfer the products and therefore are recorded as direct selling expenses, as incurred. Shipping revenue are recorded upon delivery to the customer.

curr

Practical Expedients And Exemptionspolicytextblock

PracticalExpedientsAndExemptionspolicytextblock

The Company has elected certain practical expedients and policy elections as permitted under ASC Topic 606 as follows: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">The Company adopted the practical expedient related to not adjusting the promised amount of consideration for the effects of a significant financing component if the period between transfer of product and customer payment is expected to be less than one year at the time of contract inception;</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">The Company made the accounting policy election to exclude any sales and similar taxes from the transaction price;</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">The Company adopted the practical expedient not to disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less</td></tr></tbody></table>

curr

Sales Taxpolicytextblock

SalesTaxpolicytextblock

The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to a customer, excluding sales taxes. The net amount of sales tax payable to the taxation authority is included sales tax payable in the balance sheet.

curr

Sales Returns Discounts And Warrantiespolicytextblock

SalesReturnsDiscountsAndWarrantiespolicytextblock

Sales returns, discount and warranties are considered variable consideration under ASC 606. The Company reduces revenue for estimated future returns, discounts and warranties which may occur with distributors and retailers. When evaluating the adequacy of sales returns, discounts and warranties, the Company analyzes the following: historical credit allowances, current sell-through of inventory of the Company’s products, current trends in retail industry, changes in customer demand, acceptance of products, and other related factors.

CY2020Q4

curr

Prepaid Consulting Services

PrepaidConsultingServices

14000

USD

CY2021Q2

curr

Prepaid Clinical Study

PrepaidClinicalStudy

0

USD

CY2020Q4

curr

Prepaid Clinical Study

PrepaidClinicalStudy

32000

USD

CY2021Q2

us-gaap

Prepaid Insurance

PrepaidInsurance

138000

USD

CY2020Q4

us-gaap

Prepaid Insurance

PrepaidInsurance

347000

USD

CY2021Q2

us-gaap

Other Prepaid Expense Current

OtherPrepaidExpenseCurrent

0

USD

CY2020Q4

us-gaap

Other Prepaid Expense Current

OtherPrepaidExpenseCurrent

700000

USD

CY2021Q2

curr

Prepaid Equipment

PrepaidEquipment

61000

USD

CY2020Q4

curr

Prepaid Equipment

PrepaidEquipment

61000

USD

CY2021Q2

curr

Prepaid Inventory

PrepaidInventory

175000

USD

CY2020Q4

curr

Prepaid Inventory

PrepaidInventory

211000

USD

CY2021Q2

us-gaap

Prepaid Expense Current

PrepaidExpenseCurrent

102000

USD

CY2020Q4

us-gaap

Prepaid Expense Current

PrepaidExpenseCurrent

66000

USD

curr

Contract Liabilitiespolicytextblcok

ContractLiabilitiespolicytextblcok

Advance payments and billings in excess of revenue recognized represent contract liabilities and are recorded as deferred revenues when customers remit contractual cash payments in advance before satisfying performance obligations under contractual arrangements. Contract liabilities are derecognized when revenue is recognized, and the performance obligation is satisfied. Advance payments and billings in excess of revenue recognized are included in deferred revenue, which is classified as current or noncurrent based on the timing of when the Company expects to recognize revenue. At June 30, 2021 and December 31, 2020, we had contract liabilities of $0.6 million and $1.0 million, respectively. Contract liabilities is made up of the following as of June 30, 2021 and December 31, 2020 (in thousands): <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Customer deposits for commercial products</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">597</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">281</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer deposits for personal protective equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">713</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total contract liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">597</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">994</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The following table summarizes the changes in contract liabilities during the six months ended June 30, 2021 and year ended December 31, 2020 (in thousands): <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">456</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Additions</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,033</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Transfers to Revenue</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(495 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">994</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Additions</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">591</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer deposits returned</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(713 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Transfers to Revenue</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(275 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at June 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">597</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

CY2021Q2

us-gaap

Deferred Revenue

DeferredRevenue

600000

USD

curr

Contract Liabilities Beginning Balance

ContractLiabilitiesBeginningBalance

994000

USD

us-gaap

Advertising Expense

AdvertisingExpense

1600000

USD

CY2021Q2

curr

Research And Development Expenses

ResearchAndDevelopmentExpenses

700000

USD

curr

Research And Development Expenses

ResearchAndDevelopmentExpenses

1300000

USD

CY2021Q2

us-gaap

Other Assets Current

OtherAssetsCurrent

123000

USD

CY2020Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

79000

USD

CY2021Q2

curr

Prepaid Expenses And Other Assets

PrepaidExpensesAndOtherAssets

599000

USD

CY2021Q2

curr

Current Portion Of Prepaid Expenses And Other Assets

CurrentPortionOfPrepaidExpensesAndOtherAssets

-516000

USD

CY2020Q4

curr

Current Portion Of Prepaid Expenses And Other Assets

CurrentPortionOfPrepaidExpensesAndOtherAssets

-1452000

USD

CY2021Q2

us-gaap

Other Assets

OtherAssets

83000

USD

CY2020Q4

us-gaap

Other Assets

OtherAssets

58000

USD

CY2021Q2

us-gaap

Inventory Raw Materials

InventoryRawMaterials

67000

USD

CY2020Q4

us-gaap

Inventory Raw Materials

InventoryRawMaterials

64000

USD

CY2021Q2

curr

Inventory Packaging Components

InventoryPackagingComponents

133000

USD

CY2020Q4

curr

Inventory Packaging Components

InventoryPackagingComponents

54000

USD

CY2021Q2

us-gaap

Inventory Work In Process

InventoryWorkInProcess

101000

USD

CY2020Q4

us-gaap

Inventory Work In Process

InventoryWorkInProcess

22000

USD

CY2021Q2

us-gaap

Inventory Finished Goods

InventoryFinishedGoods

714000

USD

CY2020Q4

us-gaap

Inventory Finished Goods

InventoryFinishedGoods

603000

USD

CY2021Q2

us-gaap

Inventory Gross

InventoryGross

1015000

USD

CY2020Q4

us-gaap

Inventory Gross

InventoryGross

743000

USD

CY2021Q2

us-gaap

Inventory Adjustments

InventoryAdjustments

-184000

USD

CY2020Q4

us-gaap

Inventory Adjustments

InventoryAdjustments

-294000

USD

CY2021Q2

us-gaap

Inventory Net

InventoryNet

831000

USD

CY2020Q4

us-gaap

Inventory Net

InventoryNet

449000

USD

curr

Inventory Reserves

InventoryReserves

3000.000

USD

CY2020Q2

curr

Inventory Reserves

InventoryReserves

1000.000

USD

curr

Inventory Reserves

InventoryReserves

3000.000

USD

CY2020Q4

us-gaap

Sale Leaseback Transaction Accumulated Depreciation

SaleLeasebackTransactionAccumulatedDepreciation

1091000

USD

CY2021Q2

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

1947000

USD

CY2020Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

2074000

USD

CY2021Q2

us-gaap

Depreciation

40000.00

USD

us-gaap

Depreciation

90000.00

USD

CY2020Q2

us-gaap

Depreciation

50000.00

USD

us-gaap

Depreciation

10000.00

USD

CY2021Q2

us-gaap

Allowance For Doubtful Accounts Receivable

AllowanceForDoubtfulAccountsReceivable

0

USD

CY2020Q4

us-gaap

Allowance For Doubtful Accounts Receivable

AllowanceForDoubtfulAccountsReceivable

200000

USD

CY2021Q2

curr

Current Portion Of Note Receivable Net

CurrentPortionOfNoteReceivableNet

0

USD

CY2020Q4

curr

Current Portion Of Note Receivable Net

CurrentPortionOfNoteReceivableNet

0

USD

CY2021Q2

us-gaap

Notes Receivable Gross

NotesReceivableGross

200000

USD

CY2020Q4

us-gaap

Notes Receivable Gross

NotesReceivableGross

0

USD

CY2019

curr

Patents Received From Acquisition Of Chemistry Holdings Inc

PatentsReceivedFromAcquisitionOfChemistryHoldingsInc

700000

USD

CY2019

curr

Inprocess Research And Development Received From Acquisition Of Chemistry Holdings Inc

InprocessResearchAndDevelopmentReceivedFromAcquisitionOfChemistryHoldingsInc

14500000

USD

CY2021Q2

us-gaap

Goodwill Gross

GoodwillGross

13868000

USD

CY2020Q4

us-gaap

Goodwill Gross

GoodwillGross

13868000

USD

CY2021Q2

us-gaap

Finite Lived Customer Relationships Gross

FiniteLivedCustomerRelationshipsGross

7110000

USD

CY2020Q4

us-gaap

Finite Lived Customer Relationships Gross

FiniteLivedCustomerRelationshipsGross

7110000

USD

CY2020Q4

us-gaap

Finite Lived Patents Gross

FiniteLivedPatentsGross

26917000

USD

CY2021Q2

us-gaap

Accumulated Amortization Of Other Deferred Costs

AccumulatedAmortizationOfOtherDeferredCosts

2787000

USD

CY2020Q4

us-gaap

Accumulated Amortization Of Other Deferred Costs

AccumulatedAmortizationOfOtherDeferredCosts

1312000

USD

CY2021Q2

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

24188000

USD

CY2020

curr

Interest Rate

InterestRate

0.01

pure

curr

Royalty Revenues

RoyaltyRevenues

300000

USD

CY2021Q2

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

19822000

USD

CY2021Q2

curr

Accounts Payable Factoring

AccountsPayableFactoring

1851000

USD

CY2020Q4

curr

Accounts Payable Factoring

AccountsPayableFactoring

0

USD

CY2021Q2

curr

Refunds And Returns Liability

RefundsAndReturnsLiability

356000

USD

CY2020Q4

curr

Refunds And Returns Liability

RefundsAndReturnsLiability

0

USD

CY2021Q2

curr

Accrued Interest

AccruedInterest

325000

USD

CY2020Q4

curr

Accrued Interest

AccruedInterest

194000

USD

CY2021Q2

curr

Accrued Payroll

AccruedPayroll

272000

USD

CY2020Q4

curr

Accrued Payroll

AccruedPayroll

308000

USD

CY2021Q2

us-gaap

Accrued Vacation Current And Noncurrent

AccruedVacationCurrentAndNoncurrent

248000

USD

CY2020Q4

us-gaap

Accrued Vacation Current And Noncurrent

AccruedVacationCurrentAndNoncurrent

180000

USD

CY2021Q2

us-gaap

Accrued Liabilities Current And Noncurrent

AccruedLiabilitiesCurrentAndNoncurrent

310000

USD

CY2020Q4

us-gaap

Accrued Liabilities Current And Noncurrent

AccruedLiabilitiesCurrentAndNoncurrent

306000

USD

CY2021Q2

curr

Sales Tax Payable

SalesTaxPayable

346000

USD

CY2020Q4

curr

Sales Tax Payable

SalesTaxPayable

311000

USD

CY2021Q2

curr

Accrued Expenses Net

AccruedExpensesNet

3708000

USD

CY2020Q4

curr

Accrued Expenses Net

AccruedExpensesNet

1299000

USD

CY2020Q4

us-gaap

Debt Instrument Periodic Payment Principal

DebtInstrumentPeriodicPaymentPrincipal

300000

USD

CY2021Q2

us-gaap

Debt Instrument Periodic Payment Principal

DebtInstrumentPeriodicPaymentPrincipal

200000

USD

CY2021Q2

us-gaap

Interest Expense Related Party

InterestExpenseRelatedParty

20000.00

USD

us-gaap

Interest Expense Related Party

InterestExpenseRelatedParty

40000.00

USD

us-gaap

Guarantees Indemnifications And Warranties Policies

GuaranteesIndemnificationsAndWarrantiesPolicies

The Company determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, the Company also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. The Company does not have any liability classified warrants as of any period presented.

curr

Contingencies

We are exposed to claims and litigation arising in the ordinary course of business and use various methods to resolve these matters in a manner that we believe serves the best interest of our shareholders and other constituents. When a loss is probable, we record an accrual based on the reasonably estimable loss or range of loss. When no point of loss is more likely than another, we record the lowest amount in the estimated range of loss and, if material, disclose the estimated range of loss. We do not record liabilities for reasonably possible loss contingencies, but do disclose a range of reasonably possible losses if they are material and we are able to estimate such a range. If we cannot provide a range of reasonably possible losses, we explain the factors that prevent us from determining such a range. Historically, adjustments to our estimates have not been material. We believe the recorded reserves in our consolidated financial statements are adequate in light of the probable and estimable liabilities. We do not believe that any of these identified claims or litigation will be material to our results of operations, cash flows, or financial condition.

us-gaap

Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest

IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

-4572000

USD

us-gaap

Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest

IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

-11392000

USD

curr

Common Stock And Common Stock Equivalents

CommonStockAndCommonStockEquivalents

39867063000

shares

CY2021Q2

us-gaap

Debt Instrument Convertible Conversion Price1

DebtInstrumentConvertibleConversionPrice1

1.32

CY2020Q4

curr

Convertible Promissory Notes

ConvertiblePromissoryNotes

550000

USD

CY2021Q2

us-gaap

Convertible Notes Payable Current

ConvertibleNotesPayableCurrent

550000

USD

CY2020Q4

us-gaap

Convertible Notes Payable Current

ConvertibleNotesPayableCurrent

550000

USD

CY2020Q4

curr

Current Portion Of Loan Payable

CurrentPortionOfLoanPayable

-265000

USD

CY2021Q2

curr

Loan Payable Less Current Portion

LoanPayableLessCurrentPortion

0

USD

CY2020Q4

curr

Loan Payable Less Current Portion

LoanPayableLessCurrentPortion

0

USD

CY2021Q2

us-gaap

Proceeds From Lines Of Credit

ProceedsFromLinesOfCredit

1000.000

USD

us-gaap

Proceeds From Lines Of Credit

ProceedsFromLinesOfCredit

3000.000

USD

CY2020Q2

us-gaap

Proceeds From Lines Of Credit

ProceedsFromLinesOfCredit

1000.000

USD

us-gaap

Proceeds From Lines Of Credit

ProceedsFromLinesOfCredit

2000.000

USD

CY2021Q2

us-gaap

Notes Payable Current

NotesPayableCurrent

1550000

USD

CY2020Q4

us-gaap

Notes Payable Current

NotesPayableCurrent

800000

USD

CY2021Q1

curr

Gross Proceeds Net

GrossProceedsNet

1000000.0

USD

CY2021Q2

curr

Payment Protection Program Loan

PaymentProtectionProgramLoan

0

USD

CY2020Q4

curr

Payment Protection Program Loan

PaymentProtectionProgramLoan

605000

USD

CY2021Q2

us-gaap

Commercial Paper

CommercialPaper

16510000

USD

CY2020Q4

us-gaap

Commercial Paper

CommercialPaper

18684000

USD

CY2021Q2

curr

Less Investor Note Offset

LessInvestorNoteOffset

-5000000

USD

CY2020Q4

curr

Less Investor Note Offset

LessInvestorNoteOffset

-5000000

USD

CY2021Q2

us-gaap

Debt Instrument Carrying Amount

DebtInstrumentCarryingAmount

11510000

USD

CY2020Q4

us-gaap

Debt Instrument Carrying Amount

DebtInstrumentCarryingAmount

13684000

USD

CY2021Q2

curr

Less Current Portion Of Convertible Promissory Notes At Fair Value

LessCurrentPortionOfConvertiblePromissoryNotesAtFairValue

-7221000

USD

CY2020Q4

curr

Less Current Portion Of Convertible Promissory Notes At Fair Value

LessCurrentPortionOfConvertiblePromissoryNotesAtFairValue

-6674000

USD

CY2021Q2

us-gaap

Convertible Debt Noncurrent

ConvertibleDebtNoncurrent

4289000

USD

CY2021Q2

us-gaap

Convertible Subordinated Debt

ConvertibleSubordinatedDebt

12221000

USD

CY2020Q4

us-gaap

Convertible Subordinated Debt

ConvertibleSubordinatedDebt

11674000

USD

CY2020Q4

us-gaap

Convertible Debt Noncurrent

ConvertibleDebtNoncurrent

7010000

USD

CY2020

us-gaap

Proceeds From Issuance Of Medium Term Notes

ProceedsFromIssuanceOfMediumTermNotes

1000000.0

USD

CY2020

curr

Remaining Balance Of Investor Note

RemainingBalanceOfInvestorNote

5000000.0

USD

CY2020Q4

us-gaap

Debt Instrument Convertible Conversion Price1

DebtInstrumentConvertibleConversionPrice1

1.32

CY2020

us-gaap

Debt Conversion Converted Instrument Rate

DebtConversionConvertedInstrumentRate

0.18

pure

us-gaap

Debt Conversion Converted Instrument Rate

DebtConversionConvertedInstrumentRate

0.18

pure

CY2021Q2

us-gaap

Debt Instrument Convertible Conversion Price1

DebtInstrumentConvertibleConversionPrice1

1.32

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0036

pure

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.8114

pure

curr

Expected Dividend Payout

ExpectedDividendPayout

0

USD

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P2Y

curr

Expected Forfeiture Rate

ExpectedForfeitureRate

0

CY2020Q4

curr

Prepaid Expenses And Other Assets

PrepaidExpensesAndOtherAssets

1510000

USD

curr

Change In Warrant Value

ChangeInWarrantValue

0

USD

CY2021Q2

curr

Prepaid Consulting Services

PrepaidConsultingServices

0

USD

CY2021Q2

curr

Inventory Reserves

InventoryReserves

3000.000

USD

CY2021Q2

us-gaap

Sale Leaseback Transaction Accumulated Depreciation

SaleLeasebackTransactionAccumulatedDepreciation

1185000

USD

CY2020Q4

us-gaap

Convertible Long Term Notes Payable

ConvertibleLongTermNotesPayable

200000

USD

CY2020

us-gaap

Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease

FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease

-91000

USD

us-gaap

Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease

FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease

0

USD

CY2020

curr

Derivative Liability Measured At Fair Value Ending Balance

DerivativeLiabilityMeasuredAtFairValueEndingBalance

0

USD

curr

Derivative Liability Measured At Fair Value Ending Balance

DerivativeLiabilityMeasuredAtFairValueEndingBalance

0

USD

CY2021Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

2264091

shares

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

2479849

shares

curr

Weighted Average Contractual Remaining Life Outstanding Beginning Balance

WeightedAverageContractualRemainingLifeOutstandingBeginningBalance

P8Y8M26D

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

3600364

shares

CY2020

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

1.26

curr

Weighted Average Contractual Remaining Life Granted

WeightedAverageContractualRemainingLifeGranted

P9Y2M8D

CY2020

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

0.74

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

1.76

CY2020Q4

us-gaap

Class Of Warrant Or Right Outstanding

ClassOfWarrantOrRightOutstanding

6285792

shares

curr

Weighted Average Exercise Price Outstanding Beginning Balance

WeightedAverageExercisePriceOutstandingBeginningBalance

1.52

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

1395801

shares

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

0.98

CY2020

curr

Weighted Average Contractual Remaining Life Granted

WeightedAverageContractualRemainingLifeGranted

P9Y8M4D

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

0.73

CY2021Q2

us-gaap

Class Of Warrant Or Right Outstanding

ClassOfWarrantOrRightOutstanding

7310343

shares

curr

Weighted Average Exercise Price Outstanding Ending Balance

WeightedAverageExercisePriceOutstandingEndingBalance

1.46

curr

Options Exercisable Ending Balance

OptionsExercisableEndingBalance

3471304

shares

curr

Weighted Average Exercise Price Exercisable Ending Balance

WeightedAverageExercisePriceExercisableEndingBalance

1.54

curr

Weighted Average Contractual Remaining Life Exercisable Ending Balance

WeightedAverageContractualRemainingLifeExercisableEndingBalance

P8Y21D

us-gaap

Stock Granted During Period Value Sharebased Compensation

StockGrantedDuringPeriodValueSharebasedCompensation

1100000

USD

us-gaap

Stock Granted During Period Value Sharebased Compensation

StockGrantedDuringPeriodValueSharebasedCompensation

4300000

USD

us-gaap

Share Based Compensation

ShareBasedCompensation

1200000

USD

us-gaap

Share Based Compensation

ShareBasedCompensation

400000

USD

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

60000.00

USD

curr

Goodwill From The Acquisition Of Chemistry Holdings Inc

GoodwillFromTheAcquisitionOfChemistryHoldingsInc

9200

USD

curr

Compensation Expense To Restricted Shares

CompensationExpenseToRestrictedShares

300000

USD

CY2021Q2

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

150000000

shares

CY2021Q2

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2021Q2

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

62877959

shares

CY2021Q2

us-gaap

Finite Lived Patents Gross

FiniteLivedPatentsGross

26975000

USD

CY2020Q4

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

25605000

USD

CY2019

curr

Goodwill From The Acquisition Of Chemistry Holdings Inc

GoodwillFromTheAcquisitionOfChemistryHoldingsInc

4700000

USD

CY2021Q2

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

90000.00

USD

CY2020Q2

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

30000.00

USD

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

1500000

USD

CY2021Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths

1734000

USD

CY2021Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense Rolling Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo

3411000

USD

CY2021Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense Rolling Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree

3238000

USD

CY2021Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense Rolling Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour

3075000

USD

CY2021Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense Rolling Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive

2230000

USD

CY2021Q2

us-gaap

Finite Lived Intangible Assets Amortization Expense Rolling After Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive

6134000

USD

CY2021Q2

curr

Current Portion Of Loan Payable

CurrentPortionOfLoanPayable

-46000

USD

CY2020Q3

curr

Total Balance Repaid Of Outstanding

TotalBalanceRepaidOfOutstanding

1100000

USD

curr

Schedule Of Paycheck Protection Programtabletextblock

ScheduleOfPaycheckProtectionProgramtabletextblock

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Payment Protection Program Loan due April 2022, including interest at 1% per annum; unsecured. On February 5, 2021, $0.4 million was forgiven as permitted under Section 1106 of the CARES Act.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">399</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Payment Protection Program Loan due April 2022, including interest at 1% per annum; unsecured. On June 9, 2021, $0.2 million was forgiven as permitted under Section 1106 of the CARES Act.</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">206</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Payment protection program loan</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">605</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

CY2021Q2

curr

Convertible Promissory Notes

ConvertiblePromissoryNotes

550000

USD

curr

Net Sales

NetSales

549000

USD

us-gaap

Operating Income Loss

OperatingIncomeLoss

-11485000

USD

curr

Schedule Of Promissory Notestabletextblock

ScheduleOfPromissoryNotestabletextblock

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series A subordinated convertible note at fair value</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,289</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,010</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series B subordinated convertible note at fair value</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,221</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,674</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total convertible promissory notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,510</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,684</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Investor Note offset – Series B Note</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Carrying value of convertible promissory notes at fair value</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,510</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,684</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: current portion of convertible promissory notes at fair value</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,221 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,674</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Convertible promissory notes, less current portion</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,289</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,010</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

CY2021Q2

us-gaap

Convertible Subordinated Debt Noncurrent

ConvertibleSubordinatedDebtNoncurrent

4289000

USD

CY2020Q4

us-gaap

Convertible Subordinated Debt Noncurrent

ConvertibleSubordinatedDebtNoncurrent

7010000

USD

curr

Warrant Exercisable Shares

WarrantExercisableShares

363636

shares

CY2020Q4

us-gaap

Debt Instrument Convertible Conversion Price1

DebtInstrumentConvertibleConversionPrice1

1.32

curr

Convertible Promissory Note

ConvertiblePromissoryNote

1100000

USD

CY2020

us-gaap

Debt Conversion Description

DebtConversionDescription

the Investor (and other certain related parties) would beneficially own in excess of 4.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion. This limit may, from time to time, be increased, up to 9.99%

CY2020

curr

Derivative Liability Measured At Fair Value Beginning Balance

DerivativeLiabilityMeasuredAtFairValueBeginningBalance

91000

USD

CY2020Q2

us-gaap

Assets

30157000

USD

CY2020Q2

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

43000

USD

CY2020Q2

us-gaap

Inventory Net

InventoryNet

210000

USD

CY2021Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

2264091

shares

curr

Weighted Average Remaining Contractual Life Years

WeightedAverageRemainingContractualLifeYears

P0Y9M29D

curr

Weighted Average Exercise Price

WeightedAverageExercisePrice

1.82

curr

Number Of Warrants Exercisable Weighted Average Exercise Price

NumberOfWarrantsExercisableWeightedAverageExercisePrice

1.82

CY2020Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

2479849

shares

CY2020

curr

Weighted Average Remaining Contractual Life Years

WeightedAverageRemainingContractualLifeYears

P1Y2M23D

CY2020

curr

Weighted Average Exercise Price

WeightedAverageExercisePrice

1.86

CY2020

curr

Number Of Warrants Exercisable Weighted Average Exercise Price

NumberOfWarrantsExercisableWeightedAverageExercisePrice

1.86

CY2021Q2

curr

Change In Warrant Value

ChangeInWarrantValue

0

USD

CY2020Q2

curr

Change In Warrant Value

ChangeInWarrantValue

100000

USD

curr

Change In Warrant Value

ChangeInWarrantValue

0

USD

CY2020

curr

Change In Warrant Value

ChangeInWarrantValue

0

USD

CY2019Q4

us-gaap

Class Of Warrant Or Right Outstanding

ClassOfWarrantOrRightOutstanding

3467650

shares

CY2020

curr

Weighted Average Exercise Price Outstanding Beginning Balance

WeightedAverageExercisePriceOutstandingBeginningBalance

1.84

CY2020

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

30000

shares

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

752222

shares

CY2020

curr

Weighted Average Exercise Price Outstanding Ending Balance

WeightedAverageExercisePriceOutstandingEndingBalance

1.52

CY2020

curr

Weighted Average Contractual Remaining Life Outstanding Beginning Balance

WeightedAverageContractualRemainingLifeOutstandingBeginningBalance

P8Y10M9D

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

371250

shares

curr

Weighted Average Contractual Remaining Life Outstanding Ending Balance

WeightedAverageContractualRemainingLifeOutstandingEndingBalance

P8Y8M12D

CY2021Q2

us-gaap

Share Based Compensation

ShareBasedCompensation

500000

USD

CY2020Q2

us-gaap

Share Based Compensation

ShareBasedCompensation

400000

USD

CY2020Q4

curr

Right Of Use Lease Liability Noncurrent

RightOfUseLeaseLiabilityNoncurrent

278000

USD

CY2021Q2

us-gaap

Operating Lease Liability

OperatingLeaseLiability

327000

USD

curr

Schedule Of Nonvested Restricted Award Shares

ScheduleOfNonvestedRestrictedAwardShares

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">RestrictedStock Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Grant DateFair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Non-vested, December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">82,086</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.69</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.60</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(181,849</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.08</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited/Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(237</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Non-vested, December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.60</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">320,339</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.97</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(254,954</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.07</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited/Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Non-vested, June 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">115,385</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.30</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

curr

Compensation Expense To Restricted Shares

CompensationExpenseToRestrictedShares

100000

USD

CY2021Q2

curr

Compensation Expense To Restricted Shares

CompensationExpenseToRestrictedShares

100000

USD

CY2020Q2

curr

Compensation Expense To Restricted Shares

CompensationExpenseToRestrictedShares

100000

USD

CY2021Q2

curr

Warrants Exercised Price

WarrantsExercisedPrice

1.85

CY2021Q2

curr

Debt Instrument Conversion Price

DebtInstrumentConversionPrice

1.72

curr

Schedule Of Business Segmentstabletextblock

ScheduleOfBusinessSegmentstabletextblock

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cure</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Sera Labs</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Eliminations</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">279</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,327</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(51</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,555</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Operating Loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,116</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,647</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,763</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,956</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,651</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(14,175</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,432</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts receivable, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">206</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">242</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">336</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">495</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">831</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Summary financial information for the two reportable segments for the six months ending June 30, 2020 is as follows (in thousands): <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cure</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Sera Labs</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Eliminations</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">549</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">549</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Operating Loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,485</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,485</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,157</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,157</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts receivable, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

curr

Net Sales

NetSales

3555000

USD

us-gaap

Operating Income Loss

OperatingIncomeLoss

-7763000

USD

CY2021Q2

us-gaap

Assets

44432000

USD

curr

Schedule Of Disaggregation Of Revenuetabletextblock

ScheduleOfDisaggregationOfRevenuetabletextblock

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six Months Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">CureFilm™ sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">67</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research & Development services</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Product sales - CBD</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">78</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">82</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Product sales - PPE</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">100</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">98</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">100</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">98</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>

CY2021Q2

curr

Revenues Percentages

RevenuesPercentages

17

CY2020Q2

curr

Revenues Percentages

RevenuesPercentages

10

CY2020Q2

curr

Revenue Received

RevenueReceived

10

curr

Revenues Percentages

RevenuesPercentages

98

curr

Revenues Percentages

RevenuesPercentages

10

curr

Revenue Received

RevenueReceived

81

CY2021Q2

us-gaap

Accounts And Notes Receivable Net

AccountsAndNotesReceivableNet

40000.00

USD

CY2020Q4

us-gaap

Accounts And Notes Receivable Net

AccountsAndNotesReceivableNet

130000

USD

curr

Estimated Acquisition Costs

EstimatedAcquisitionCosts

4000000.0

USD

curr

Fair Value Of The Contingent Share Consideration

FairValueOfTheContingentShareConsideration

3205

USD

curr

Fair Value Beginning Balance

FairValueBeginningBalance

1650000

USD

curr

Net Change In Fair Value During The Year Ended December312019

NetChangeInFairValueDuringTheYearEndedDecember312019

-1555000

USD

curr

Schedule Of Preliminary Estimated Fair Value Of Assetstabletextblock

ScheduleOfPreliminaryEstimatedFairValueOfAssetstabletextblock

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">(Dollars in thousands)</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Upfront Payment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Closing Merger Consideration Shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,909,091</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,535</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Contingent Consideration Shares (Clawback Shares)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,988,024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,083</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities assumed</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">550</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total purchase price</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,897,115</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">14,168</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;">(Dollars in thousands)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Net assets acquired:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,357</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,440</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Property, plant and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other long term assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">384</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Intangibles assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,182</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Goodwill</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,687</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts payable and accrued expenses</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,063</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Contract liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,963</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other current liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(462 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other long-term liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(400 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net assets acquired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">14,168</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

curr

Schedule Of Sera Labs Acquisitionstabletextblock

ScheduleOfSeraLabsAcquisitionstabletextblock

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">(Dollars in thousands)</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted-average Estimateduseful life</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">PreliminaryEstimated AssetFair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Finite-lived intangible assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;white-space: nowrap;"> </td><td>5.0 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,110</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Tradename</td><td style="width:1%;white-space: nowrap;"> </td><td>4.0 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,610</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Non-compete</td><td style="width:1%;white-space: nowrap;"> </td><td>2.0 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">462</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total finite-lived intangible assets acquired</td><td style="width:1%;white-space: nowrap;"> </td><td>4.6 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,182</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

us-gaap

Acquired Finite Lived Intangible Assets Weighted Average Useful Life

AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife

P4Y7M6D

curr

Preliminary Estimated Asset Fair Value

PreliminaryEstimatedAssetFairValue

10182000

USD

CY2019Q2

curr

Upfront Payment Consideration

UpfrontPaymentConsideration

5700000

shares

CY2019Q2

curr

Claw Back Shares

ClawBackShares

7128913

shares

CY2019Q2

curr

Earnout Shares

EarnoutShares

8018071

shares

CY2020Q4

curr

Warrants Issue Purchase Additional Shares

WarrantsIssuePurchaseAdditionalShares

4143706000000

shares

CY2019Q2

curr

Potential Shares

PotentialShares

32072283

shares

CY2020

curr

Potential Shares

PotentialShares

26372283

shares

curr

Fair Value Contingent Share Consideration Beginning Balance

FairValueContingentShareConsiderationBeginningBalance

16043000

USD

curr

Settlement Of Contingent Consideration Liability

SettlementOfContingentConsiderationLiability

-21701000

USD

curr

Net Change In Fair Value

NetChangeInFairValue

-5658000

USD

curr

Fair Value Ending Balance

FairValueEndingBalance

0

USD

curr

Net Loss Attributable Tabletextblock

NetLossAttributableTabletextblock

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cure Pharmaceutical</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Sera Labs</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Pro formaAdjustments</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated Pro Forma</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net product sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">269</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,327</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,596</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net income (loss)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(13,349</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(13,345</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net income (loss) attributable to Cure per common share:, basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.25</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.32</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.25</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> For the six months ended June 30, 2020 (in thousands, except per share data): <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cure Pharmaceutical</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Sera Labs</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Pro formaAdjustments</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated Pro Forma</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net product sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">549</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,940</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,489</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(11,392</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(357 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(11,749</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss attributable to Cure per common share:, basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.29</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.03</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.23</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.29</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.03</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.23</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>

CY2019Q4

curr

Feasibility Study And Technology Cost

FeasibilityStudyAndTechnologyCost

300000

USD

CY2021Q2

curr

Revenue Other

RevenueOther

0

USD

CY2020Q2

curr

Revenue Other

RevenueOther

50000.00

USD

curr

Revenue Other

RevenueOther

0

USD

curr

Revenue Other

RevenueOther

10000.00

USD

CY2020Q2

curr

Sum Of Installment Payment Description

SumOfInstallmentPaymentDescription

a gross sum of $93,461.54, paid in equal installments over a six-month period; (ii) for a period of six months, an amount equal to the cost of her COBRA health benefits if she enrolls for COBRA coverage;

CY2021Q2

us-gaap

Finance Lease Liability Payments Due

FinanceLeaseLiabilityPaymentsDue

100000

USD

CY2021Q2

us-gaap

Operating Leases Rent Expense Net

OperatingLeasesRentExpenseNet

100000

USD

CY2020Q2

us-gaap

Operating Leases Rent Expense Net

OperatingLeasesRentExpenseNet

70000.00

USD

CY2021Q2

us-gaap

Finance Lease Liability Current

FinanceLeaseLiabilityCurrent

200000

USD

curr

Weighted Average Discount Rate

WeightedAverageDiscountRate

11.30

us-gaap

Operating Leases Rent Expense Net

OperatingLeasesRentExpenseNet

100000

USD

CY2021Q2

curr

Right Of Use Asset

RightOfUseAsset

300000

USD

curr

Schedule Of Future Lease Paymentstabletextblock

ScheduleOfFutureLeasePaymentstabletextblock

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;">Years</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2021 (remaining)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">134</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Undiscounted cash flow</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">384</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effects of discounting</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(57</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lease liabilities recognized</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">327</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

CY2021Q2

us-gaap

Other Commitment Due In Next Twelve Months

OtherCommitmentDueInNextTwelveMonths

66000

USD

CY2021Q2

us-gaap

Other Commitment Due In Second Year

OtherCommitmentDueInSecondYear

134000

USD

CY2021Q2

us-gaap

Other Commitment Due In Third Year

OtherCommitmentDueInThirdYear

138000

USD

CY2021Q2

us-gaap

Other Commitment Due In Fourth Year

OtherCommitmentDueInFourthYear

46000

USD

CY2021Q2

us-gaap

Other Commitment Due In Fifth Year

OtherCommitmentDueInFifthYear

0

USD

CY2021Q2

curr

Undiscounted Cash Flow

UndiscountedCashFlow

384000

USD

CY2021Q2

curr

Effect Of Discounting

EffectOfDiscounting

-57000

USD

CY2021Q2

curr

Lease Liabilities Recognized

LeaseLiabilitiesRecognized

327000

USD

CY2021Q2

us-gaap

Capital Leases Future Minimum Payments Due In Three Years

CapitalLeasesFutureMinimumPaymentsDueInThreeYears

14000

USD

curr

Description Of Finance Lease

DescriptionOfFinanceLease

the Company entered into a 5-year equipment lease rental which requires the Company to pay monthly payments of $0.02 million. The Company determined the payments represented substantially all of the fair value of the asset and recorded a right of use asset for $0.06 million and a finance lease liability for $0.06 million during the year ended December 31, 2019 within other assets and liabilities. The company will make payment of $0.02 annually until October 2024. Interest associated with the lease is $0.1 million or less annually based on a discount rate of 9.0%. As of June 30, 2021

CY2021Q2

us-gaap

Capital Leases Future Minimum Payments Due Current

CapitalLeasesFutureMinimumPaymentsDueCurrent

9000

USD

CY2021Q2

us-gaap

Capital Leases Future Minimum Payments Due In Two Years

CapitalLeasesFutureMinimumPaymentsDueInTwoYears

14000

USD

CY2021Q2

us-gaap

Capital Leases Future Minimum Payments Due In Four Years

CapitalLeasesFutureMinimumPaymentsDueInFourYears

9000

USD

CY2021Q2

us-gaap

Capital Leases Future Minimum Payments Due In Five Years

CapitalLeasesFutureMinimumPaymentsDueInFiveYears

0

USD

CY2021Q2

us-gaap

Capital Leases Future Minimum Payments Due Thereafter

CapitalLeasesFutureMinimumPaymentsDueThereafter

0

USD

CY2021Q2

curr

Finance Lease Liabilities Recognized

FinanceLeaseLiabilitiesRecognized

46000

USD

CY2021Q2

us-gaap

Operating Lease Right Of Use Asset

OperatingLeaseRightOfUseAsset

301000

USD

CY2020Q4

us-gaap

Operating Lease Right Of Use Asset

OperatingLeaseRightOfUseAsset

343000

USD

CY2021Q2

curr

Right Of Use Lease Liabilities Current

RightOfUseLeaseLiabilitiesCurrent

100000

USD

CY2020Q4

curr

Right Of Use Lease Liabilities Current

RightOfUseLeaseLiabilitiesCurrent

93000

USD

CY2021Q2

curr

Right Of Use Lease Liability Noncurrent

RightOfUseLeaseLiabilityNoncurrent

227000

USD

CY2020Q4

us-gaap

Operating Lease Liability

OperatingLeaseLiability

371000

USD

CY2021Q2

curr

Finance Lease Right To Use Assets Net

FinanceLeaseRightToUseAssetsNet

46000

USD

CY2020Q4

curr

Finance Lease Right To Use Assets Net

FinanceLeaseRightToUseAssetsNet

52000

USD

CY2021Q2

curr

Liabilities Current Financing Leases

LiabilitiesCurrentFinancingLeases

12000

USD

CY2020Q4

curr

Liabilities Current Financing Leases

LiabilitiesCurrentFinancingLeases

12000

USD

CY2021Q2

us-gaap

Finance Lease Liability Noncurrent

FinanceLeaseLiabilityNoncurrent

34000

USD

CY2020Q4

us-gaap

Finance Lease Liability Noncurrent

FinanceLeaseLiabilityNoncurrent

40000

USD

CY2021Q2

curr

Total Financing Leases Liabilities

TotalFinancingLeasesLiabilities

46000

USD

CY2020Q4

curr

Total Financing Leases Liabilities

TotalFinancingLeasesLiabilities

52000

USD

curr

Weighted Average Remaining Lease Term Operating Lease

WeightedAverageRemainingLeaseTermOperatingLease

P2Y9M18D

CY2020

curr

Weighted Average Remaining Lease Term Operating Lease

WeightedAverageRemainingLeaseTermOperatingLease

P3Y3M21D

curr

Weighted Average Remaining Lease Term Finance Lease

WeightedAverageRemainingLeaseTermFinanceLease

P3Y3M21D

CY2020

curr

Weighted Average Remaining Lease Term Finance Lease

WeightedAverageRemainingLeaseTermFinanceLease

P3Y9M25D

curr

Weighted Average Discount Rate

WeightedAverageDiscountRate

11.30

CY2020

curr

Weighted Average Discount Rate

WeightedAverageDiscountRate

11.3

curr

Finance Leases Weighted Price

FinanceLeasesWeightedPrice

9.0

CY2020

curr

Finance Leases Weighted Price

FinanceLeasesWeightedPrice

9.0

Name	View Source	Status
0001477932-21-005635-index-headers.html	Edgar Link	pending
0001477932-21-005635-index.html	Edgar Link	pending
0001477932-21-005635.txt	Edgar Link	pending
0001477932-21-005635-xbrl.zip	Edgar Link	pending
curr-20210630.xsd	Edgar Link	pending
curr-20210630_cal.xml	Edgar Link	unprocessable
curr-20210630_def.xml	Edgar Link	unprocessable
curr-20210630_lab.xml	Edgar Link	unprocessable
curr-20210630_pre.xml	Edgar Link	unprocessable
curr_10q.htm	Edgar Link	pending
curr_10q_htm.xml	Edgar Link	completed
curr_ex311.htm	Edgar Link	pending
curr_ex312.htm	Edgar Link	pending
curr_ex321.htm	Edgar Link	pending
curr_ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVRW
Avenir Wellness Solutions, Inc. Stock $avrw

2021 Q2 Form 10-Q Financial Statement

#000147793221005635 Filed on August 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVRW Avenir Wellness Solutions, Inc. Stock $avrw

2021 Q2 Form 10-Q Financial Statement

#000147793221005635 Filed on August 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVRW
Avenir Wellness Solutions, Inc. Stock $avrw